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Dopaminergic neurons of the nigrostriatal dopaminergic system, projecting from 
the substantia nigra compacta (SNc) to the striatum, serve a critical role in mediating 
voluntary motor control.  Parkinson’s disease is a neurological disorder characterized by 
progressive degeneration of these dopamine neurons, which leads to dopaminergic 
deficiencies in the striatum.  Reduced striatal dopamine transmission is thought to 
increase inhibitory basal ganglia output to the thalamus and subsequently reduce 
excitation of cortical motor areas, resulting in impaired motor functioning.  Despite 
unclear mechanisms, deep brain stimulation (DBS) is an established neurosurgical 
approach for effectively treating the parkinsonian motor symptoms.  Currently the 
subthalamic nucleus (STN) is the most commonly targeted site in these procedures, while 
the pedunculopontine tegmental nucleus (PPT) is emerging as a therapeutically beneficial 
target when stimulated alone or in combination with the STN.  Thus, the connectivity 
between these nuclei and the nigrostriatal dopamine system is the focus of the present 
paper, with the overarching hypothesis being that the therapeutic benefits of STN/PPT 
DBS are mediated, at least in part, by activation of surviving nigrostriatal neurons, 
resulting in striatal dopamine release.  The present study investigated several neural 
pathways and receptor mechanisms involved in mediating STN or PPT stimulation-
evoked striatal dopamine release using in vivo fixed potential amperometry with carbon-
fiber recording microelectrodes in the striatum of urethane-anesthetized mice.  Overall, 
results indicate that STN stimulation evokes striatal dopamine release directly via 
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excitatory glutamatergic inputs to SNc dopamine cells as well as indirectly by activating 
excitatory glutamatergic and cholinergic STN-PPT-SNc pathways, while PPT stimulation 
evokes striatal dopamine release directly by activating glutamatergic and cholinergic 
pathways to SNc dopamine cells as well as indirectly via activation of glutamatergic and 
cholinergic PPT-STN-SNc projections.  Understanding the influence of the STN and PPT 
on SNc dopamine cell activity and output of the basal ganglia-thalamocortical motor 
circuit may lead to novel pharmaceutical therapies as well as a better understanding of the 
underlying mechanisms of clinical DBS, which could then improve the therapeutic 







This dissertation has been formatted to allow for the separate publication of Chapter 5 
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Chapter 1. Overview of the Nigrostriatal Dopamine System 
 
The nigrostriatal dopaminergic system projects predominantly from the substantia 
nigra compacta (SNc) of the midbrain to the caudate putamen (striatum in the rat) of the 
forebrain (Albanese and Minciacchi, 1983).  Stimulation of the SNc elicits fast excitatory 
responses in striatal neurons (Plenz and Kitai, 1996), while lesions of the SNc reduce 
basal levels of extracellular striatal dopamine concentrations (Dentresangle et al., 2001).  
In addition, striatal extracellular dopamine concentration is positively correlated with the 
degree of dopamine cell loss in the SNc (Altar et al., 1987).  Dopamine transmission in 
the striatum is most commonly associated with voluntary movements and has been linked 
to the selection and initiation of contextually appropriate motor patterns (Hauber, 1998; 
Redgrave et al., 1999; Wickens, 1990).  Reduced dopamine in the striatum is associated 
with motor symptoms of Parkinson’s disease such as difficulty initiating and terminating 
movements, gait impairments, and muscular rigidity (Knott et al., 1999; Lev et al., 2003; 
Wolters and Francot, 1998), whereas excess dopamine release in the striatum can lead to 
repetitive motoric behaviors such as stereotypy, with the degree of intensity of 
stereotypical behaviors (e.g. body rearing, head bobbing, and gnawing) being positively 
correlated with striatal dopamine release (Sharp et al., 1987).  
 
Physiology of the Basal Ganglia 
The basal ganglia are comprised of the striatum, substantia nigra, subthalamic 
nucleus (STN), and globus pallidus. Anatomists have made further distinctions based on 
structure and function. The substantia nigra has been divided into the SNc and substantia 
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nigra reticulata (SNr), while the globus pallidus comprises lateral segments, namely the 
globus pallidus externus (GPe) and the globus pallidus internus (GPi).  The putative role 
of the basal ganglia is to synthesize multiple sources of information from sensual, 
emotional, associative brain areas in order to produce a contextually appropriate response 
(Bolam et al., 2000).  The major input station for the basal ganglia is the striatum, with 
the majority of neurons within this area being spiny γ-aminobutyric acid (GABA) 
containing projection neurons, 2% of striatal neurons being large cholinergic 
interneurons, and the rest being aspiny GABAergic interneurons (Hauber, 1998; Parent 
and Hazrati, 1995).  The spiny GABAergic neurons are the main targets for most 
projections to the striatum (Parent and Hazrati, 1995), with dopamine receptor subtypes 
of these cells being both dopamine D1-like (D1 and D5) and D2-like (D2, D3, and D4) 
receptors (Wooten, 2001).  As illustrated in Fig. 1, the neurons of the striatum project to 
other areas within the basal ganglia complex, the GPi and the SNr, via two pathways, a 
direct (monosynaptic) connection and an indirect pathway through the external segment 
of the globus pallidus (GPe) and the subthalamic nucleus (STN).  Striatal neurons in the 
direct pathway utilize D1 receptors, whereas those in the indirect pathway utilize D2 
receptors (Galvan and Wichmann, 2008; Gerfen et al., 1990). Activation of D1 receptors 
stimulates adenylate cyclase activity, thus activating the GABAergic medium spiny 
output neurons, whereas activation of D2 receptors inhibits adenylate cyclase, thus 
inhibiting GABAergic output neurons (Wooten, 2001).  Therefore, the direct (via D1) 
and indirect (via D2) pathways have opposing actions, but may reach the same net 
outcome of activating motor regions of the cortex. For example, activation of D1 
receptors in the direct striatal GABAergic pathway leads to inhibition of GPi/SNr 
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inhibitory GABAergic projections to the thalamus, subsequently increasing activity in the 
thalamus that, in turn, excites motor areas in the cortex (Gerfen et al., 1990; Mink, 1996; 
Wooten, 2001).  Alternatively, activation of D2 receptors in the indirect pathway inhibits 
striatal inhibitory GABAergic neurons, resulting in disinhibition (excitation) of GPe 
inhibitory GABAergic neurons that project to the STN.  As a consequence, decreased 
activity of the STN excitatory glutamatergic neurons that innervate the GPi/SNr, GPe, 
and SNc leads to a reduced inhibitory drive of these nuclei to the thalamus, thereby 
indirectly increasing excitation of the motor areas in the cortex (Gerfen et al., 1990; 
Mink, 1996; Wooten, 2001).  In sum, the net effect of striatal dopamine release from the 
nigrostriatal pathway increases thalamocortical activity via direct or indirect reduction of 






Fig. 1. Simplified thalamocortical basal ganglia circuitry depicting the innervation of the 
striatum by the nigrostriatal dopaminergic system and its excitatory and inhibitory 
influence on the direct (via D1 receptors) and indirect (via D2 receptors) GABAergic 
striatal output pathways to the globus pallidus internus/substantia nigra reticulata 
(GPi/SNr).  The glutamatergic and cholinergic neurons of the pedunculopontine 
tegmental nucleus (PPT) connect with the basal ganglia via excitatory projections to the 
subthalamic nucleus (STN), substantia nigra compacta (SNc), and GPi/SNr.  ACh: 
acetylcholine; DA: dopamine; GABA: γ-aminobutyric acid; Glu: glutamate; GPe: globus 






STN and PPT Connectivity and Modulation of Striatal Dopamine Release 
The STN comprises a relatively small bilateral pair of brain nuclei, located in the 
diencephalon close to the dorsal forebrain bundle (Hauber, 1998; Lee et al., 2006).  The 
majority of STN neurons are projection neurons which are glutamatergic in nature (Albin 
et al., 1989; Smith and Parent, 1988; Van der Kooy and Hattori, 1980).  The STN 
projects to many areas of the basal ganglia, with high amounts of collateralization, 
including the globus pallidus, SNr, and the SNc (Deniau et al., 1978; Hauber, 1998).  
These connections, specifically the direct excitatory efferent to the SNc, place the STN in 
a critical position to regulate dopamine activity in the striatum (Groenewegen and 
Berendse, 1990; Hammond et al., 1978; Kita and Kitai, 1987).  The STN also projects to 
the pedunculopontine tegmental nucleus (PPT), offering an alternate route of mediating 
activity of the nigrostriatal dopamine system via the PPT’s connectivity with the basal 
ganglia (Groenewegen and Berendse, 1990; Morrizumi and Hattori, 1992).  The PPT, 
located in the mesopontine region of the hindbrain, contains a heterogeneous population 
of cholinergic and glutamatergic neurons.  PPT projections to the STN, GPi, SNc, cortex, 
and thalamus have been identified, with the densest of these projections going to the SNc 
and STN (Charara et al., 1996; Clarke et al., 1997; Lee et al., 2000; Pahapill and Lozano, 
2000). This prompts interest in the question of exactly how the STN and PPT may 
interact to differentially modulate nigrostriatal dopaminergic neurotransmission given 
their extensive interconnectivity and high degree of collateralization with many important 
nigrostriatal related structures. 
 Research supports a contribution of the STN in modulating functional activity of 
the nigrostriatal dopamine system. Stimulation of the STN has been shown to alter 
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neuronal activity within the SNc of rodents generating both excitatory and inhibitory 
postsynaptic potentials (Lee et al., 2004; Nakanishi et al., 1987) and increased firing of 
SNc neurons (Benazzou et al., 2000; Hammond et al., 1978; Iribe et al., 1999).   
Electrical stimulation of the STN has also been shown to increase dopamine extracellular 
levels in the striatum (Lee et al., 2006).  Pharmacological activation via microinfusion of 
the GABA antagonist bicuculline into the STN produced enhancements in not only STN 
neuronal firing, but also in SNc and globus pallidus neuron activity (Chergui et al., 1994; 
Robledo and Feger, 1990).  Intra-STN infusion of kynurenate, which non-selectively 
antagonizes ionotropic glutamate receptors, attenuates spontaneous activity of SNc 
neurons (Robledo and Feger, 1990).  Most of the aforementioned studies utilized rodents; 
however, changes in STN activity have also been shown to significantly affect discharge 
patterns of SNc neurons and striatal dopamine release similarly in primates (Charara et 
al., 1996; Futami et al., 1995).  However, the monosynaptic pathway between the STN 
and SNc has shown to be sparse in primates compared to rodents (Sato et al., 2000; Smith 
et al., 1990). Thus, changes in SNc discharge patterns following pharmacological 
stimulation and inhibition of the STN in primates have been suggested to be mediated 
primarily by excitatory SNc afferents from the PPT (Charara et al., 1996; Futami et al., 
1995).  The STN and PPT are reciprocally connected with excitatory projections (Futami 
et al., 1995; Lee et al., 2000), which have been shown to be both cholinergic and 
glutamatergic from the PPT to the STN (Moon-Edley and Graybiel, 1983; Oakman et al., 
1999).  In vivo electrochemical studies have previously shown that electrical and 
chemical stimulation of the PPT enhances dopamine efflux in the striatum (Forster and 
Blaha, 2003; Miller and Blaha, 2004); thus, stimulation of the STN may be increasing 
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discharge patterns of SNc dopaminergic neurons and generating striatal dopamine release 
indirectly through activation of the PPT.   
 Evidence illustrating the functional importance of the PPT supports a critical 
modulatory role of this brain region in the modulation of nigrostriatal dopaminergic 
activity.  As noted above, excitatory glutamatergic and cholinergic neuronal cells in the 
PPT directly project to dopamine-containing cell bodies in the SNc (Blaha and Winn, 
1993; Forster and Blaha, 2003; Moon-Edley and Graybiel, 1983; Oakman et al., 1999).  
Pharmacological activation of the PPT with ionotropic glutamate receptor agonists 
increases both the firing rate of SNc dopamine neurons (Clarke et al., 1987) and 
dopamine metabolism within the striatum as measured by in vivo voltammetry 
(Hernandez-Lopez et al., 1992).  Electrical stimulation of the PPT has also been shown to 
activate STN neurons via cholinergic and glutamatergic projections (Hammond et al., 
1983; Woolf and Butcher, 1986).  Therefore, in addition to direct activational inputs to 
SNc dopaminergic cells, the PPT may also modulate nigrostriatal dopamine activity in an 
indirect manner, through PPT glutamatergic and cholinergic inputs to STN glutamatergic 
neurons that, in turn, innervate dopamine-containing cells in the SNc (Bevan and Bolam, 
1995; Lee et al., 2000).  An understanding of how these brain regions functionally 
interact to mediate nigrostriatal dopamine release is essential in enhancing our knowledge 
on how these pathways normally function to affect sensory-motor gating in the striatum.  
Such an understanding will give insight and greater clarity into neurological disorders 
such as Parkinson’s disease which arise as a result of abnormal functioning of the 




Behavioral Correlates of Striatal Dopamine Release 
Dopamine transmission in the striatum is most commonly associated with normal 
voluntary ballistic movements (Wickens, 1990).  Increasing striatal dopamine levels with 
psychostimulants such as the amphetamines in animals leads to the production of 
repetitive and contextually redundant stereotypic behaviors, which includes behaviors 
such as repetitive rocking, self-grooming, sniffing, and gnawing.  Indeed, early in vivo 
microdialysis studies have demonstrated that the presentation of these behaviors is 
correlated with abnormally high levels of striatal dopamine release (Sharp et al., 1987).  
Furthermore, stereotypy may be induced and subsequently attenuated by microinfusions 
of dopamine receptor agonists and antagonists, respectively, into the striatum (Canales 
and Graybiel, 2000; Presti et al., 2003).  It is thought that dopaminergic receptor agonists 
and antagonists infused in the striatum may enhance or reduce GABAergic medium spiny 
neurons activity, respectively, ultimately resulting in an enhancement or reduction in 
communication to motor cortical areas.  Thus, excessive striatal dopamine levels are 
thought to alter the output of striatal projection neurons (via the direct or indirect output 
pathways) leading to reduced activity of the GPi/SNr, as seen in hyperkinetic disorders 
such as Huntington’s disease (Mink, 1996).  
 In contrast, marked reduction or absence of dopamine in the striatum leads to an 
overall increase in activity of the GPi/SNr, which in turn reduces neurotransmission in 
motor cortical areas and impairs motor control (Mink, 1996; Wooten, 2001).   Animals 
treated with 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), which are commonly used chemicals for inducing 
degeneration of nigrostriatal dopamine neurons,  demonstrate significantly low levels of 
9 
 
locomotion as well as muscular rigidity, slowness of movement, and abnormal posture 
(Langston et al., 1984; Truong et al., 2006).  Thus, these animal models mimic the 
neuropathology as well as behavioral symptomology seen in Parkinson’s disease.  In 
clinical cases of Parkinson’s disease, as well as 6-OHDA-lesioned rats and MPTP-
lesioned monkeys, administration of indirect dopamine agonists such as levodopa, 
dramatically ameliorates motor symptoms (Konitsiotis et al., 2000; Murer et al., 1998; 
Olanow et al., 2006).  Furthermore, chronic treatment or acute high doses of indirect 
dopamine agonists such as levodopa can induce dyskinesias, which can be eliminated by 
either lowering the levodopa dose or pharmacologically reducing activity of SNc 
dopamine neurons (Obeso et al., 2002).  In sum, the ultimate effect of dopamine release 
in the striatum, arising from SNc dopamine neurons is to facilitate movement and 




Chapter 2. Parkinson’s Disease 
 
Motor Symptoms and Neuropathology of Parkinson’s Disease 
Parkinson’s disease is a neurological disorder affecting up to 3 percent of people 
aged 65 and over worldwide (Lang and Lozano, 1998; Zhang and Roman, 1993).  Mean 
age of onset is now thought to be in the early-to-mid 60s, but has in some cases occurred 
as early as mid 40s (Inzelberg et al., 2002).  Parkinson’s disease is characterized 
primarily by motor symptoms that include bradykinesia (slowness in movement), tremor, 
rigidity, postural instability, and gait impairments, with nonmotor symptoms such as 
sleep disturbances and cognitive impairment appearing also (Jankovic, 2008).  The 
principal pathology associated with Parkinson’s disease is the degeneration of dopamine-
containing neurons in the substantia nigra compacta (SNc), a critical component of the 
nigrostriatal dopamine system (Wolters and Francot, 1998).  Degeneration of SNc 
dopamine neurons subsequently results in dopamine deficiencies within the caudate-
putamen (striatum) of the forebrain (Lev et al., 2003).  Reduced dopamine levels in the 
striatum disrupts the normal functioning of the basal ganglia-thalamocortical motor 
circuit, which plays a critical role in regulating motor activity (Knott et al., 1999; Lev et 
al., 2003; Wolters and Francot, 1998).  Specifically, a reduction in striatal dopaminergic 
transmission, as in the parkinsonian condition, is thought to increase inhibitory output 
from the basal ganglia to the thalamus leading to a reduction in excitation of primary 
motor areas of the cortex, resulting in impaired motor functioning.  Fig. 1 depicts changes 
in the overall activity of basal ganglia-thalamocortical motor circuit related to 
Parkinson’s disease (modified from Galvan and Wichmann, 2008).   In Parkinson’s 
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disease, the degeneration of SNc dopamine neurons and their projections to the striatum 
is a slowly evolving process occurring over decades, a very heinous aspect of this 
disease.  SNc projections to the areas of the striatum related to motor function degenerate 
earlier than projections to associative or limbic portions of the striatum; therefore, the 
motor symptoms of Parkinson’s disease develop and are often detectable before the non-
motor symptoms.  Clinical motor symptoms are observed with at least 80% decrease in 
striatal dopamine content and at least 50% or greater loss of dopaminergic neurons in the 




Fig. 1. Simplified depiction of Parkinsonism-related changes in overall activity of the 
thalamocortical basal ganglia motor circuitry.  Blue arrows indicate dopaminergic 
projections.  Red arrows indicate excitatory glutamatergic projections, and black arrows 
indicate inhibitory GABAergic projections.  The thickness of the arrows corresponds to 
their presumed activity; such that the thicker lines indicate more activation, and the 
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dotted lines indicate less activation. GPe: globus pallidus externus; GPi: globus pallidus 




Evidence implicating nigrostriatal dysfunction in Parkinson’s disease arises from 
a number of sources including postmortem brain analysis and functional imaging 
techniques.  Post mortem analysis of Parkinsonian brains have demonstrated a marked 
degeneration of dopamine-containing cells in the SNc, as well as reduced expression of 
dopamine transporters and synaptic vesicle amine transporter gene expression (Fearnley 
and Lees, 1991; Knott et al., 1999; Zweig et al., 1989).  Interestingly research also 
demonstrates significant reductions in neurons within the pedunculopontine tegmental 
nucleus (PPT), a hindbrain region which as discussed in Chapter 1 is known to critically 
contribute to the functioning of the nigrostriatal dopamine system via its glutamatergic 
and cholinergic projections to the SNc (Blaha and Winn, 1993; Chapman et al., 1997; 
Jellinger, 1988; Zweig et al., 1989).  Additionally, significant loss of neurons within the 
PPT has also been found to correlate with the extent of neuronal loss of dopamine cells in 
the SNc (Zweig et al., 1989).  Structural magnetic resonance imaging (MRI) studies have 
noted decreased width of the SNc in Parkinson’s patients (Duguid et al., 1986; 
Hutchinson and Raff, 2000), and as expected, volumetric MRI analysis of parkinsonian 
brains have shown diminished volumes in subcortical nuclei including the striatum 
(Lisanby et al., 1993; Oneill et al., 2002).  Functional neuroimaging is mainly used 
experimentally but has become useful in clinical trials aimed at measuring the 
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progression of Parkinson’s disease (Whone et al., 2003).  As measured by positron 
emission tomography (PET), Parkinson’s disease is characterized by decreased striatal 6-
[
18
F]-fluoro-L-dopa (F-DOPA) uptake (Vingerhoets et al., 1994), which is highly 
correlated with reduced dopamine cell counts measured in post mortem brains (Snow et 
al., 1993). 
 
Animal Models of Parkinson’s Disease 
Animal models of Parkinson’s disease have also yielded strong supporting 
evidence for a neuropathology of the nigrostriatal dopamine system in this disorder.  
Studies that have selectively lesioned components of the nigrostriatal dopamine system 
(e.g. SNc, striatum) through the application of specific neurotoxins, one of the most 
common being the catecholamine neurotoxin 6-hydroxydopamine (6-OHDA), have 
reported close approximations of the extent of the neurodegeneration seen in Parkinson’s 
disease (Cousins and Salamone, 1996; Deumans et al., 2002).  At a behavioral level, 6-
OHDA lesioned animals demonstrate motor abnormalities in skilled and fine movements, 
as well as deficits in locomotor activity.  Furthermore, such animal models demonstrate 
that significant lesions of the nigrostriatal dopamine system that reduce dopamine striatal 
tissue content by approximately 80% produce motor difficulties akin with Parkinson’s 
disease.  Interestingly, excitotoxic lesions of the PPT have also been found to produce 
parkinsonian type postural deficits, hypokinesia and locomotor deficits in primates 
(Kojima et al., 1997; Pahapill and Lozano, 2000).   
Another neurotoxin commonly used to mimic Parkinson’s disease neuropathology 
in animals is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  During the early 
14 
 
1980’s, a number of individuals unwittingly injected a potent pyridine derivative related 
to the non-opioid analgesic Demerol which was contaminated with MPTP by virtue of a 
sloppy synthesis and sold on the streets as “China White”, a synthetic heroin (Ballard et 
al., 1985; Langston et al., 1983). Exposure to MPTP produced selective 
neurodegeneration of the nigrostriatal dopamine system resulting in the development of 
severe bradykinesia, postural deficits, and motor rigidity similar to that seen in 
Parkinson’s disease (Langston et al., 1999; Snow et al., 2000).  The serendipitous 
discovery of MPTP and its parkinsonian symptoms offered new avenues in researching 
Parkinson’s disease, and new MPTP animal models of Parkinson’s disease emerged.  The 
MPTP primate model of human Parkinson’s disease has also provided additional 
evidence that the nigrostriatal dopamine system is particularly important in the etiology 
of this disease.   MPTP treated primates develop motor abnormalities closely resembling 
those seen in humans with Parkinson’s disease, with deficits including bradykinesia, 
rigidity, postural abnormalities and postural tremor, and rest tremor in some primate 
species (Kanda et al., 2000; Maratos et al., 2001; Schapira, 2002).  For this reason, MPTP 
administration in primates is considered the most predictive model for antiparkinsonian 
efficacy of novel drugs in humans (Gerlach and Riederer, 1996).  In sum, animal models 
such as these suggest that interfering with neural areas that importantly influence 
nigrostriatal dopamine activity may contribute to the severe motor abnormalities 
associated with Parkinson’s disease.  Also, these animal models have been very useful in 
studying the therapeutic strategies for motor symptom treatment and potential 




Etiology of Parkinson’s Disease 
The etiology for the vast majority of Parkinson’s disease cases is largely unknown 
and thus classified as idiopathic.  Controversy exists as to how much of the disease 
results from a strictly genetic cause, a purely environmental factor, or a combination of 
the two (Di Monte, 2003; Farrer, 2006).   Thus, despite the overwhelming evidence 
implicating nigrostriatal dysfunction in Parkinson’s disease, the precise cause for 
neuronal loss and deficient dopaminergic activity within the nigrostriatal dopamine 
system remains unclear.  Several mechanisms have been proposed for the cell death 
associated with Parkinson’s disease, including oxidative stress and excitotoxicity.  
Oxidative stress is an adverse effect that occurs when the generation of highly reactive 
free radicals exceeds the system’s ability to neutralize and eliminate them, resulting in 
damage to the cellular membrane lipids, proteins, and DNA (for review see Simonian and 
Coyle, 1996).  Post mortem brains of Parkinson’s patients have shown increased amounts 
of free radical damage indicators, such as lipid peroxidation and oxidized DNA (Alam et 
al., 1997; Dexter et al., 1989).  6-OHDA is selectively taken up by dopaminergic neurons 
(and other catecholaminergic neurons near site of infusion) and causes oxidative stress 
and ultimately cell degeneration (Cohen and Heikkila, 1974).  Oxidative stress is also 
thought to participate in MPTP-induced toxicity of dopamine neurons (Zang and Misra, 
1993).  For this reason, antioxidant approaches for neuroprotective therapies seem 
warranted and have shown preclinically to protect against MPTP toxicity and 6-OHDA 
lesioning in animal models. It is important to note however, clinical trials assessing the 
effectiveness of antioxidants as neuroprotective agents for Parkinson’s disease have been 
inconclusive, with transient results at best (Alexi et al., 2000). 
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It has also been proposed that the neurodegeneration associated with Parkinson’s 
disease may result from increased glutamatergic transmission in the SNc, most likely due 
to overactivity and burst firing of STN neurons (Johnson et al., 2009).  Glutamate 
receptors, specifically N-methyl-D-aspartic acid (NMDA) receptors, are known to 
mediate excitotoxicity caused by high levels of glutamate.  Therefore, activation of these 
receptors in the SNc may contribute to the degeneration of dopamine neurons in this 
region (Waxman and Lynch, 2005).  In support of this argument, NMDA antagonists 
have been noted to reduce or delay SNc degeneration and motor deficits caused by MPTP 
administration or 6-OHDA lesioning (Johnson et al., 2009).  These results support the 
hypothesis that NMDA receptor activation contributes to neurodegeneration in 
Parkinson’s disease and suggest that blockade of NMDA receptors may be a useful 
strategy for slowing disease progression.  However, the widespread expression and 
diverse functional roles of NMDA receptors raise concern that targeting these receptors 
would lead to serious unwanted side effects.  Clinical studies have therefore used weak 
NMDA receptor antagonists and have generally failed to find any therapeutic benefit 
when administered alone (without levodopa) (Johnson et al., 2009).  More promising 
studies suggest that selectively targeting NMDA receptor subtypes specific to regions 
relevant to Parkinson’s disease pathophysiology may represent safer neuroprotective 
options (Jin et al., 1997).  As such, further clinical studies using more selective drugs 
targeting NMDA receptors are needed.   In sum, the specific factors that contribute to or 
initiate overly active NMDA mechanisms in excitotoxicity are poorly understood, and the 
potential contribution of other types of glutamate receptors to the development and 
progression of Parkinson’s disease symptoms remains unclear. 
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Treatments for the Motor Symptoms of Parkinson’s Disease 
The most effective pharmaceuticals for treating the motor symptoms of 
Parkinson’s disease are drugs that restore dopaminergic function in the striatum, with the 
most commonly prescribed being the dopamine precursor levodopa (Olanow et al., 2004).  
Levodopa is usually combined with carbidopa (Lodosyn) or benserazide (Serazide) as 
Sinemet or Prolopa, respectively, to prevent peripheral conversion of levodopa to 
dopamine by dopa-decarboxylase (Olanow et al., 2004).  Dopamine synthesized from 
levodopa activates both D1 and D2 receptors in the striatum, which is important 
therapeutically as antiparkinsonian drugs with high D2 and low D1 affinity have been 
shown to be less effective in reversing motor symptoms compared to levodopa (Wooten, 
2001).  Conjoint use of levodopa with drugs that inhibit dopamine-degrading enzymes 
(e.g. monoamine oxidase inhibitors) within surviving dopamine nerve terminals have 
further been shown to enhance the therapeutic effects of levodopa alone, presumably by 
slowing the metabolic breakdown of dopamine, while the conjunctive use of 
dopaminergic agonists with levodopa has also proved therapeutically beneficial during 
later stages of Parkinson’s disease (Hurtig, 1997).  In fact, levodopa has been used to 
distinguish Parkinson's disease from other conditions that may resemble Parkinson's 
disease, a true testament to the reliability of levodopa for treating the motor symptoms of 
Parkinson’s disease.  Reduced motor symptoms following a single administration of 
levodopa can help to confirm the diagnosis of Parkinson’s disease, and a negative 
response is thought to be an indication for alternative diagnosis (D’Costa et al., 1995).    
While levodopa treatment provides relief of motor symptoms for several years in 
most patients, complications occur with long-term use.  As dopaminergic neurons 
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continue to deteriorate, the levodopa dose is effective for a shorter time, and the patient 
experiences “wearing off” sooner.  Motor fluctuations can also become unpredictable 
with sudden switches between good therapeutic response (i.e. mobility) and no 
therapeutic response (i.e. immobility), referred to as the “on-off” phenomenon (Marsden 
and Parkes, 1976).  Also, increased doses of levodopa leads to abnormal involuntary 
movements (e.g. dyskinesia and leg dystonia), which can be lessened by reduction of the 
dose, but the dose decrease then generally leads to loss of control of the disease.  These 
motor complications have an incidence of 10% per year, so that after taking levodopa 5 
years roughly 50% of patients experience these detrimental side effects (Rajput et al., 
1984; Rascol et al., 2000).  Patients therefore become increasingly disabled even with 
treatment, which is a particular problem given that levodopa remains the most effective 
treatment for Parkinson’s disease despite these serious drawbacks.  Thus, novel 
pharmaceuticals as well as interventive neurosurgical treatments, such as deep brain 
stimulation, are continuously being explored and refined for better management of the 
motor symptoms associated with Parkinson’s disease.  Advances in our understanding of 
the connectivity and function of the basal ganglia circuitry will continue to open the door 




Chapter 3. Deep Brain Stimulation as a Treatment for Parkinson’s Disease 
 
Parkinson’s disease is a neurological disorder characterized by a progressive 
degeneration of the dopamine neurons in the substantia nigra compacta (SNc) and a 
subsequent reduction in striatal dopamine levels (Obeso et al., 2002).  Parkinson’s 
disease treatments attempt to alleviate symptoms by restoring dopamine transmission in 
the striatum (Clarke, 2004).  Although oral administration of the dopamine precursor 
levodopa, the most commonly prescribed pharmaceutical for ameliorating the motor 
symptoms of Parkinson’s disease, is highly effective for several years in most patients, as 
the disease progresses with time chronic levodopa treatment is associated with the 
development of complications, such as motor fluctuations and dyskinesias, which can be 
just as problematic as the disease itself (Marsden and Parkes, 1976; Rascol et al., 2000).  
When patients reach this stage, interventive neurosurgery such as deep brain stimulation 
(DBS) is an option to consider.  Because of the limitations of the current available 
pharmaceutical treatments and the efficacy and favorable safety profile of DBS, this 
interventive neurosurgical treatment approach is now approved by the US Food and Drug 
Administration and is routine in clinical use for treatment of Parkinson’s disease (Krack 
et al., 2003).  The application and substantial progress of functional neurosurgery rank 
amongst the most significant of therapeutic advances in Parkinson’s disease, perhaps 
second only to the introduction of levodopa.    
DBS involves implanting electrodes with four contacts into the target area of the 
brain and connecting it to an implanted pulse generator usually located in the chest area, 
much like a pacemaker for the heart.  Conventional DBS systems use a relatively high-
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frequency (100-250 Hz) pulse train applied continuously at the site of electrode 
implantation (McIntyre et al., 2006).  One key aspect permitting reliable therapeutic 
benefits of this procedure is that stimulation parameters provided by the implanted pulse 
generator can be adjusted postoperatively to improve efficacy, reduce side-effects, and 
adapt to the course of the disease.  Results from clinical trials have repeatedly shown that 
DBS plus medical therapy improves patient quality of life as well as clinical scores on the 
Unified Parkinson’s Disease Rating Scale more than the best medical therapy alone 
(Deuschl et al., 2006; Weaver et al., 2009; Williams et al., 2010).  The most common 
target for DBS in Parkinson’s disease is the subthalamic nucleus (STN) as this 
ameliorates the cardinal symptoms of the disease (i.e. bradykinesia, rigidity, and tremor) 
while at the same time reducing medication needs for the patient (Limousin et al., 1998; 
Molineuvo et al., 2000; Moro et al., 1999; Volkmann et al., 2001).    
 
Hypotheses of the Mechanism of Action of DBS  
Despite the acceptance of DBS as a well qualified therapeutic tool for treating the motor 
symptoms of Parkinson’s disease, the mechanism of action of DBS remains poorly 
understood and debated in research.  Because the therapeutic effects of DBS are similar 
to those of a lesion of targeted nuclei, whether it is the STN (for Parkinson’s  disease), 
globus pallidus interna (for generalized dystonia), or ventrointermedial nucleus of the 
thalamus (for essential tremor), DBS has been thought to silence neurons at the site of 
stimulation (Benazzouz et al., 1995; Lozano et al., 2002).  However, emerging evidence 
is beginning to discredit neuronal silencing hypothesis and, as such, implicates additional 
mechanisms of DBS, which involve activation of local neuronal terminals at the site of 
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stimulation that inhibit and/or excite efferent outputs.  In turn, this has been postulated to 
enhance efferent neurotransmission, which may ultimately normalize activity within 
structures of the basal ganglia complex (see Benabid, 2003; Lozano and Eltahawy, 2004; 
McIntyre et al., 2004; Uc and Follett, 2007).  Specifically, recent studies have shown that 
DBS results in excitation and altered firing patterns of neurons in the STN (Carlson et al., 
2010; Garcia et al, 2003; Lee et al., 2007), increased activity in dopaminergic neurons of 
the SNc (Lee et al., 2003, 2004), as well as enhanced dopamine release in the striatum 
(Lee et al., 2006).  These findings have lead to the “dopamine release” hypothesis which 
proposes that STN DBS improves motor symptoms related to Parkinson’s disease by 
activating surviving nigrostriatal dopaminergic neurons and subsequent increases in 
striatal dopamine release (Lee et al., 2009).  Several studies using in vivo microdialysis 
have shown that STN DBS increases dopamine metabolites DOPAC and HVA in the 
striatum of normal and 6-hydroxydopamine (6-OHDA) lesioned rats (Meissner et al., 
2001, 2002, 2003; Paul et al., 2000).  Furthermore, DBS of the STN decreases or 
eliminates the need for levodopa (Molineuvo et al., 2000; Moro et al., 1999) and is most 
effective in patients who have responded well to levodopa (Breit et al.,2004), suggesting 
that effective DBS requires endogenous dopamine production.  Also consistent with the 
notion that STN DBS activates surviving nigrostriatal dopamine neurons are clinical 
observations that DBS can generate dyskinesias resembling those seen when excess 
levodopa is given (Frank et al., 2007).  
While supporting evidence from basic research is available, the hypothesis that 
DBS of the STN contributes to symptom relief in Parkinson’s disease due to an evoked 
increase in striatal dopamine release remains controversial.  Two major techniques in 
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basic research studies have provided the majority of findings that oppose the dopamine 
release hypothesis.  First, most basic studies using in vivo microdialysis do not report an 
increase in striatal dopamine release during stimulation of the STN in intact or 6-OHDA 
lesioned animals (Bruet et al., 2001; Meissner et al., 2001; Paul et al., 2000).  Although in 
vivo monitoring of slow (min-hrs) changes in dopamine release is easily accomplished 
using conventional microdialysis methods, analysis of more rapid changes in dopamine 
release that may result from STN DBS requires an equally rapid “real-time” detection 
and monitoring system.  Second, several positron emission tomography (PET) studies 
using [11C]-raclopride binding to measure dopamine release have failed to demonstrate 
significant raclopride displacement despite improvements in motor performance 
following STN DBS (Abosch et al., 2003; Hilker et al., 2003; Strafella et al., 2003).  
However, PET scanning with raclopride has relatively poor temporal resolution and 
requires an increase of greater than 90% of baseline measures in order to detect a change 
in dopamine receptor populations (Hilker et al., 2003; Volkow et al., 1993).  Thus, it 
seems likely that inconsistencies in the literature may be due to technical difficulties in 
measuring striatal dopamine release.  Whether STN DBS improves Parkinson’s disease 
motor symptoms via increased release of dopamine in the striatum is the overall focus 
connecting the experimental studies in Chapters 5 and 6.  For this reason, in order to 
avoid the issues of temporal resolution and sensitivity seen in other techniques, these 
experimental studies involve real-time monitoring of striatal dopamine release following 
electrical stimulation using fixed potential amperometry (FPA), which offers the highest 
temporal resolution and sensitivity to monitor changes in dopamine release evoked by 
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electrical stimulation of all in vivo neurochemical recording methods to date (Venton et 
al., 2002). 
 
Candidate Pathways Mediating DBS-evoked Striatal Dopamine Release  
There are several neuronal pathways by which STN DBS could elicit dopamine release in 
the striatum.  First, stimulation of the glutamatergic input that projects from the STN to 
the SNc has been shown to activate nigrostriatal dopaminergic pathways directly 
(Meltzer et al., 1997).  Second, stimulation of the glutamatergic neurons of the STN 
projecting to the pedunculopontine tegmental nucleus (PPT) indirectly activates 
nigrostriatal dopamine neurons via reciprocal excitatory innervation back to the STN 
which leads to subsequent SNc activation by the aforementioned glutamatergic inputs 
(Lee et al., 2000) and by activating excitatory cholinergic and glutamatergic inputs from 
the PPT to the SNc (Blaha and Winn, 1993; Forster and Blaha, 2003).  As is mentioned in 
Chapter 1 and expanded upon in Chapter 5, the interconnectivity between the PPT and 
nuclei within the basal ganglia potentially provides the PPT an interesting position in 
which to mediate nigrostriatal dopamine activity (Mena-Segovia et al., 2008).  
The improvement in motor symptoms in Parkinson’s patients has been correlated 
with the location and electrical intensity of chronic stimulation (Garcia et al., 2005), and 
therapeutic outcomes of DBS have suggested that the best improvement in symptoms is 
obtained when stimulating the white matter corresponding to myelinated axons of 
passage in the region of the zona incerta just immediately dorsal to the STN (Saint-Cyr et 
al., 2002; Voges et al., 2002).  DBS in this region likely results in stimulation of 
dopaminergic axons within the medial forebrain bundle (MFB) projecting from the SNc 
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to the striatum. Thus, thirdly, DBS of the STN may be activating surviving nigrostriatal 
dopamine neurons in Parkinson’s patients via direct stimulation of the MFB. In fact, it 
has been postulated that DBS of the MFB may be superior to DBS of the STN in 
enhancing dopamine release in the striatum (Lee et al., 2006).  These candidate neural 
pathways are expanded upon and investigated systematically in the experimental studies 
in Chapters 5 and 6.  Understanding the underlying mechanisms of DBS and the neural 
pathways affected could lead to improvements in stimulation locations and parameters, 
which may prove invaluable in improving DBS interventive neurosurgical procedures 




Chapter 4. Fixed Potential Amperometry Methodology 
 
The experimental studies in Chapters 5 and 6 utilize in vivo fixed potential amperometry 
(FPA), an electrochemical method that has been valuable in elucidating the modulation of 
forebrain dopamine activity by other neurotransmitter systems (Blaha et al., 1996, 1997; 
Floresco et al., 1998; Lester et al., 2008).  Like many in vivo amperometric recording 
techniques, FPA uses a three-electrode configuration that incorporates an auxiliary 
electrode (typically platinum, chrom-alloy or stainless-steel wire), reference electrode 
(normally silver/silver chloride) and recording electrode (see Fig. 1) (Blaha and Phillips, 
1996).  In the experiments of Chapters 5 and 6, the procedure specifically involves the 
implantation of a carbon fiber recording electrode and the placement of a silver/silver 
chloride reference and stainless-steel auxiliary electrode combination in contact with 
brain tissue.  An electrometer and analog to digital chart recorder (EA162 Picostat and 
ED401 e-corder 401, eDAQ Inc., Colorado Springs, CO, USA; simply referred to as the 
electrometer in all other chapters) creates a circuit between the three electrodes, allowing 
the application of a fixed continuous potential (+0.8 V) to the recording electrode via the 
auxiliary electrode, while maintaining a potential difference between the recording and 
reference electrode (Blaha and Phillips, 1992).  Continuously applying a potential to the 
recording electrode allows dopamine to be continuously oxidized at the electrode surface.  
As such, FPA allows a high temporal resolution (10,000 samples/sec or higher dependent 
on the analog to digital converter of the recording device) for the analysis of dopamine 
neurotransmission in vivo.  Pharmacological studies have validated the selectivity of FPA 
as a measurement of electrically-stimulated dopamine efflux in vivo (Dugast et al., 1994; 
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Forster and Blaha, 2003; Lee et al., 2006).  For example, this has been demonstrated by 
significant increases in laterodorsal tegmentum stimulation-evoked oxidation current in 
the nucleus accumbens and subthalamic nucleus stimulation-evoked oxidation current in 
the striatum of rats in response to systemic administration of the dopamine reuptake 
inhibitor nomifensine, but not following serotonin or norepinephrine reuptake blockade 
with fluoxetine or desipramine (Lee et al., 2006).  Consequently, this in vivo technique 
has been utilized commonly to evaluate the kinetics of stimulation-evoked dopamine 
release and reuptake and drug-induced changes in the magnitude and temporal pattern of 
dopamine neurotransmission, as well as the biochemical basis of dopaminergic cell burst 
firing in anesthetized rats and mice (Benoit-Marand et al., 2000; Dugast et al., 1994; 







Fig. 1. Simplified diagram of a three-electrode system used in amperometric 
electrochemical recordings.  The electrometer applies an electrical potential to the 
auxiliary (AUX) electrode that is suitable to oxidize dopamine (DA) at the surface of the 
recording electrode (RE), which is held constant relative to the reference electrode (REF).  
Oxidized dopamine molecules transfer electrons to the RE which are measured as current 
flow via the electrometer (EA162 Picostat) and passed as an analog signal to the analog 
to digital chart recorder and (ED401 e-corder 401) where it is converted to a digital signal 
for display via Chart software on a computer monitor in near real time. Adapted from 







Electrochemical Recording Electrodes Used in FPA 
Polyacrylic nitrile, pitch, or pyrolytic-based carbon provides an electrochemically inert 
surface covered with oxygen-containing functional groups that facilitate electron transfer 
from compounds undergoing oxidation or reduction at the electrode surface (Kawagoe et 
al., 1993).  Carbon fiber microelectrodes to record stimulation-evoked dopamine release 
in vivo were fashioned by threading a single carbon fiber (10 m o.d.) through a 
borosilicate glass capillary tube.  The tube was then heat-pulled to form a tip through 
which the carbon fiber protruded.  Carbon paste was packed into the bore of the electrode 
and a wire inserted to make contact with the fiber.  The wire was secured in place with a 
carbon paste (super glue mixed with carbon powder) (see Fig. 2).  The protruding carbon 
fibers were cut under a stereomicroscope so that the active recording electrode surface 
was approximately 250 m long.  A new carbon fiber recording electrode was used in 
each animal. As a consequence of its small size, the carbon fiber recording electrode 
results in minimal tissue damage at the site of insertion and allows for high degree of 
local specificity for assessment of regional differences in neurochemical efflux 
(Stamford, 1989).  Moreover, the small size enables faster sampling of the dopamine 
oxidation current as there is less depletion of the neurochemical at the electrode surface 








Fig. 2.  Illustration of the carbon fiber recording electrode fabricated for use in fixed 
potential amperometry to monitor the oxidation of dopamine (corresponding to dopamine 
efflux) in vivo. 
 
 
Stereotaxic Surgery and Recording Set-up for FPA 
Anesthetized mice are mounted in a stereotaxic frame (David Kopf Instruments, Tujunga, 
CA, USA) within a mouse head-holder adaptor (Stoelting, Wood Dale, IL, USA).  
Stereotaxic coordinates for each of the target sites, which include the subthalamic nucleus 
(STN), medial forbrain bundle (MFB), pedunculopontine tegmental nucleus (PPT), 
substantia nigra compacta (SNc), and striatum in Chapters 5 and 6, are determined from 
the mouse atlas of Paxinos and Franklin (2001).  As shown in Fig. 3, in each mouse a 
concentric bipolar stimulating electrode (SNE-100; Rhodes Medical Co., CA, USA), a 31 
g stainless-steel guide infusion cannula, and a carbon fiber recording microelectrode is 
implanted into the desired brain sites.  A silver/silver chloride reference and stainless-






Fig. 3. Schematic diagram of the mouse brain illustrating a typical setup for in vivo fixed 
potential amperometric recording of stimulation-evoked striatal dopamine release.  In the 
experiments in Chapters 5 and 6, a carbon fiber recording electrode is positioned in the 
striatum.  A stimulating electrode is positioned in the dorsal portion of the medial 
forebrain bundle (MFB), subthalamic nucleus (STN), or pedunculopontine tegmental 
nucleus (PPT).  A silver/silver chloride reference and stainless-steel auxiliary electrode 
combination is placed in contact with contralateral cortical tissue, and a drug infusion 
cannula is implanted into the PPT, STN, or substantia nigra compacta (SNc). 
 
 
Amperometric recordings are made within a Faraday cage to increase the signal to 
noise ratio (Forster and Blaha, 2003).  The stimulation site varies (MFB, STN, or PPT) to 
accommodate the aim of each project, but the stimulation protocol consists of twenty 0.5 
msec duration pulses at 50 Hz delivered every 30 sec over a 1 hour testing period, 
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delivered to the stimulating electrode via an optical isolator and programmable pulse 
generator (Iso-Flex/Master-8; AMPI, Jerusalem, Israel).  With the addition of 
microinfusions of drugs, FPA lends itself to the investigation of the role of receptor 
subtypes in stimulation-evoked phasic dopamine efflux.  Intracerebral infusions of the 
local anesthetic lidocaine is an effective means of temporarily blocking all axonal 
transmission to or from specific areas and pathways with recovery approximately 10 min 
post-infusion (Blaha et al., 1997; Floresco et al., 1998).  This drug procedure offers a 
unique means to determine the functional neuroconnectivity of DBS-mediated striatal 
dopamine release and the relationship between DBS target sites, such as the MFB, STN, 
or PPT.  By temporarily blocking transmission through one of these sites, it is possible to 
determine whether DBS of these structures evokes striatal dopamine transmission via 
direct or indirect routes to the SNc.  Furthermore, infusions of specific receptor 
antagonists help determine the neurochemical nature of the neuronal pathways involved 
in mediating stimulation-evoked striatal dopamine release.  To confirm that the observed 
drug effects are not attributable to non-specific effects of the microinfusion procedure, 
microinfusions of sterile phosphate-buffered saline (PBS, pH~7.4) served as a control. 
 
Post-Experiment Procedures 
Upon the completion of each FPA session, the stimulation, recording, and infusion sites 
are marked, either by lesioning or stain infusion.  After euthanasia, the brains are 
removed and properly stored until sectioning.  Coronal sections are sliced in a cryostat 
and observed under a light microscope to confirm that the placements of stimulating 
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electrodes, recording electrodes, and drug infusion cannulae are within the anatomical 
boundaries of the target site.   
The mean change in dopamine oxidation current, corresponding to stimulation-
evoked dopamine efflux, is converted to mean dopamine concentration (µM) by post-
experiment in vitro calibration of the carbon fiber electrode in solutions of dopamine (2-
10 µM) using a flow injection system (Michael and Wightman, 1999). For each animal, 
changes in stimulation-evoked dopamine concentration after infusion were expressed as 
mean percent changes with respect to pre-infusion baseline responses (100%) and are 
subsequently averaged across animals.  The appropriate statistical tests are then 





Chapter 5. Neural Pathways Mediating Striatal Dopamine Release following High 
Frequency Stimulation: Relevance to DBS as a Treatment for Parkinson’s Disease 
 
Deep brain stimulation (DBS) is an established interventive neurosurgical approach for 
effectively treating the motor symptoms of Parkinson’s disease (Benabid, 2003; Krack et 
al., 2003).  The most common stimulation site for DBS as a treatment for Parkinson’s 
disease is the subthalamic nucleus (STN); however, the pedunculopontine tegmental 
nucleus (PPT) is emerging as a therapeutically beneficial target when stimulated by itself 
or in combination with the STN (Stefani et al., 2007).  Thus, the connectivity between 
these two nuclei and the basal ganglia is the focus of the present paper.  Despite the 
acceptance of DBS as a therapeutic tool for treating parkinsonian motor symptoms, 
which onset with at least 80% decrease in striatal dopamine content and 50% or greater 
loss of dopaminergic neurons in the substantia nigra compacta (SNc) (Fearnley and Lees, 
1991; Samii et al., 2004), the mechanism of action of DBS remains poorly understood 
and debated in research.  Because the therapeutic effects of DBS are similar to those of a 
lesion, DBS has been thought to act by silencing neuronal activity at the site of 
stimulation (Benazzouz et al., 1995; Lozano et al., 2002).  However, emerging evidence 
implicates additional mechanisms, which involve activation of local neuronal terminals at 
the site of DBS that inhibit and/or excite efferent outputs.  In turn, this has been 
postulated to enhance efferent neurotransmission, which may ultimately normalize 
activity within structures of the basal ganglia complex (Benabid, 2003; Lozano and 
Eltahawy, 2004; McIntyre et al., 2004; Uc and Follett, 2007).  Specifically, recent studies 
in rodents have shown that electrical stimulation of the STN results in excitation of 
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neurons in the STN (Garcia et al, 2003; Lee et al., 2007), increased activity in 
dopaminergic neurons of the SNc (Lee et al., 2003, 2004), as well as enhanced dopamine 
release in the striatum (Lee et al., 2006).  These findings have led to the “dopamine 
release” hypothesis which proposes that STN DBS improves motor symptoms related to 
Parkinson’s disease, in part, by activating surviving nigrostriatal dopamine neurons and 
subsequently increasing striatal dopamine release (Lee et al., 2009).  DBS of the STN has 
been shown to decrease or eliminate the need for levodopa (Molineuvo et al., 2000; Moro 
et al., 1999) and is most effective in patients who have responded well to levodopa (Breit 
et al., 2004).  Thus, clinical findings support the dopamine release hypothesis by 
suggesting endogenous dopamine production is required for DBS to be therapeutically 
successful.  Furthermore, DBS can generate dyskinesias resembling those seen when 
excess levodopa is given (Frank et al., 2007).   
STN DBS could elicit dopamine release in the striatum through activation of a 
number of neural pathways.  First, stimulation of the glutamatergic neurons that project 
from the STN to the SNc have been shown to activate nigrostriatal dopaminergic neurons 
directly (Meltzer et al., 1997).  Second, stimulation of glutamatergic neurons of the STN 
projecting to the PPT may indirectly activate nigrostriatal dopamine neurons via both 
reciprocal excitatory innervation back to the STN which leads to subsequent SNc 
activation by the aforementioned glutamatergic inputs (Lee et al., 2000) and/or by 
activating excitatory cholinergic and glutamatergic PPT neuronal projections to the SNc 
(Blaha and Winn, 1993; Forster and Blaha, 2003).  Thirdly, DBS of the STN may 
activate nigrostriatal dopamine neurons via direct stimulation of the dorsal portion of the 
medial forebrain bundle (MFB) within the zona incereta. Therapeutic outcomes of DBS 
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have suggested that the best symptom improvements result when stimulating the white 
matter just dorsal to the STN (Saint-Cyr et al., 2002; Voges et al., 2002).  DBS in this 
region likely results in stimulation of dopaminergic axons within the MFB passing 
directly from the SNc to the striatum.  Thus, it is conceivable that DBS directly aimed at 
the MFB may be superior to STN DBS in enhancing striatal dopamine release (Lee et al., 
2006).  Therefore, the present study also conducted experiments designed to determine 
the neuronal pathways involved in evoking striatal dopamine release via stimulation of 
the MFB. 
In regards to DBS of the PPT, the interconnectivity between the PPT and nuclei 
within the basal ganglia complex allows the PPT to play a critical role in the modulation 
of nigrostriatal dopaminergic activity (Forster and Blaha, 2003; Miller and Blaha, 2004; 
Mena-Segovia et al., 2008), which may explain the findings from recent clinical trials 
showing that DBS of the PPT is effective in ameliorating parkinsonian motor symptoms, 
particularly gait and postural disabilities (Stefani et al., 2007).  Thus, the present study 
also investigated the relative influence of cholinergic and glutamatergic PPT projections 
in eliciting striatal dopamine release.  Previous work from our lab using in vivo 
chronoamperometry has shown that PPT stimulation elicits striatal dopamine release, in 
which dopamine release could be blocked by intra-SNc infusions of nicotinic and 
muscarinic acetylcholine receptor (nAchR and mAchR, respectively), and ionotropic 
glutamate receptor (iGluR) antagonists (Forster and Blaha, 2003).   However, in addition 
to direct excitatory inputs to SNc dopaminergic cells, as noted above, the PPT may also 
indirectly activate these dopaminergic cells via cholinergic and glutamatergic projections 
36 
 
to excitatory glutamatergic neurons in the STN that, in turn, innervate SNc dopaminergic 
cells (Bevan and Bolam, 1995; Lee et al., 2000).   
To-date no studies have systematically examined these candidate pathways as to 
their relative involvement in mediating the effects of MFB, STN, or PPT DBS on striatal 
dopamine release.  Therefore, the present studies investigated these potential pathways in 
vivo using fixed potential amperometry (FPA) with carbon fiber microelectrodes 
positioned in the striatum to record striatal dopamine efflux evoked by DBS-like high 
frequency electrical stimulation (HFS) of the MFB, STN, or PPT.  By temporarily 
blocking transmission through various nuclei via microinfusions of the local anaesthetic 
lidocaine, we were able to determine whether HFS of the MFB, STN, or PPT evokes 
striatal dopamine transmission via direct or indirect routes to the SNc and their relative 
importance in mediating these effects.  Furthermore, infusions of specific receptor 
antagonists helped to uncover the neurochemical nature of the pathways that mediate 
MFB, STN, and PPT stimulation-evoked striatal dopamine release. 
 
Experimental Procedures 
The following experiments were approved by the Institutional Animal Care and Use 
Committee at the University of Memphis and conducted in accordance with the National 
Institutes of Health Guidelines for the Care and Use of Laboratory Animals.  Efforts were 






Animals and surgery 
Seventy-six male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA), 8-11 
weeks of age and weighing 20-27 g at the time of surgery, were used. Animals were 
housed five per cage in a temperature controlled environment (21 + 1ºC) with a 12 h 
light: 12 h dark cycle (lights on at 0600 h).  Food and water were available ad libitum.  
Mice were anesthetized with urethane (1.5 g/kg, i.p.) and mounted in a stereotaxic frame 
(David Kopf Instruments, Tujunga, CA, USA) within a mouse head-holder adaptor 
(Stoelting, Wood Dale, IL, USA), ensuring the skull was flat.  Body temperature was 
maintained at
 
36 ± 0.5°C with a temperature-regulated heating pad (TC-1000; CWE Inc., 
New York, NY, USA).  Determined from the mouse atlas of Paxinos and Franklin 
(2001), stereotaxic coordinates (AP from bregma, ML from midline, and DV from dura, 
all in mm) for each target site were as follows: striatum: AP 1.4, ML +1.4, DV -2.5; 
MFB: AP -2.0, ML +1.1, DV -4.0; STN: AP -2.0, ML +1.6, DV -4.0; SNc: AP -3.1, ML 
+1.5, DV -3.8; PPT: AP -4.7, ML +1.25, DV -2.7).  In each mouse a concentric bipolar 
stimulating electrode (SNE-100; Rhodes Medical Co., CA, USA) was implanted into the 
left MFB, STN, or PPT of each mouse.  A 31 g stainless-steel guide infusion cannula was 
implanted into the left SNc, STN, or PPT with the tip of the guide cannula positioned 2 
mm above site.  An Ag/AgCl reference and stainless-steel auxiliary electrode 
combination was placed in surface contact with contralateral cortical tissue 
approximately 2.0 mm posterior to bregma, and a carbon fiber recording microelectrode 
with an active recording surface of 250 μm (length) by 10 μm (o.d.) (Thornel Type P, 




FPA and electrical stimulation 
All amperometric recordings were made within a Faraday cage to increase the signal to 
noise ratio (Forster and Blaha, 2003).  A fixed potential (+0.8 V) was applied to the 
recording electrode, and oxidation current was monitored continuously (10K 
samples/sec) with an electrometer filtered at 50 Hz.  Approximately 10 min following 
implantation of the recording electrode, a series of 0.5 ms duration cathodal monophasic 
current pulses (20 pulses at 50 Hz applied every 30 sec over a 1 hr recording period) was 
delivered to the stimulating electrode via an optical isolator and programmable pulse 
generator (Iso-Flex/Master-8; AMPI, Jerusalem, Israel).  Intensity levels were set at 800 
µAmps in the MFB and PPT and 400 µAmps in the STN as determined by preliminary 
studies to be optimal for each target site. Intensity levels were also lower in the STN in an 
attempt to conclusively limit the stimulation region to the STN.  FPA coupled with 
carbon fiber microelectrodes has been confirmed as a valid technique for real-time 
monitoring of changes in striatal dopamine oxidation current evoked by brief electrical 
stimulation of afferent inputs to midbrain dopamine neurons (Dugast et al., 1994; Forster 
and Blaha, 2003; Lester et al., 2008).  
 
Drug microinfusions 
Microinfusions were performed by first backloading the drug into a fibreglass cannula 
(80 m o.d., Polymicro Tech. Inc., AZ, USA) connected via PE10 tubing to a 5 l 
microsyringe (Scientific Glass Engineering Inc., Austin, TX, USA) mounted on a 
microinfusion pump (Stoelting, Wood Dale, IL, USA).  After a 10 min electrical 
stimulation baseline recording period, the cannula was inserted 2 mm beyond the tip of 
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the implanted guide cannula, and 1.0 µl infusions were made over a 1.5 min period.  
Infusions of the local anesthetic lidocaine (4%) were performed to temporarily block 
axonal transmission to or from the infusion sites (Blaha et al., 1997; Floresco et al., 
1998).  By temporarily blocking transmission through the SNc, STN, or PPT, we were 
able to determine whether HFS of the MFB, STN, or PPT evokes striatal dopamine 
transmission via direct or indirect routes to the SNc.  Furthermore, in order to assess the 
relative contributions of GluRs and AchRs in the SNc and STN in mediating stimulation-
evoked striatal dopamine release, MFB, STN, or PPT-evoked striatal dopamine release 
was monitored in separate groups of mice before and during intra-SNc or STN infusions 
of the iGluR antagonist kynurenate (1 µg), the metabotropic GluR (mGluR) antagonist 
(+)-methyl-4-carboxyphenylglycine (MCPG; 1 µg), the mAchR antagonist scopolamine 
(10 µg), the nAchR antagonist mecamylamine (1 µg), or a combination of these drugs.  
To confirm that observed drug effects were not attributable to non-specific effects of the 
microinfusion procedure, microinfusions of 1.0 µl of sterile phosphate-buffered saline 
(PBS, pH~7.4) were also performed.  See Table 1 for the complete list of experimental 
groups.  The microinfusion cannula was left in place over the duration of the experiment.  
All drugs were prepared immediately before use at doses determined by preliminary 








Table 1.  Drugs used to assess the contributions of cholinergic and glutamatergic 






Drug Target receptors 
% Change    
from baseline 
MFB SNc PBS –  - 2% ± 1 
MFB SNc Lidocaine axonal + 62% ± 12 
MFB SNc Kynurenate iGluRs - 3% ± 4 
MFB PPT PBS – - 3% ± 1 
MFB PPT Lidocaine axonal - 4% ± 4 
STN SNc PBS – - 4% ± 2 
STN SNc Lidocaine axonal - 84% ± 3 
STN PPT PBS – - 1% ± 3 
STN PPT Lidocaine axonal - 46% ± 6 
STN SNc Kynurenate iGluRs - 46% ± 4 
STN SNc MCPG mGluRs - 3% ± 1 
STN SNc Scopolamine mAchRs - 28% ± 5 
STN SNc Mecamylamine nAchRs - 28% ± 5 
PPT SNc PBS – - 2% ± 2 
PPT SNc Lidocaine axonal - 90% ± 3 
PPT STN PBS – - 5% ± 3 
PPT STN Lidocaine axonal - 50% ± 8 




mAchRs + nAchRs - 26% ± 3 






Data collation and statistical analysis 
MFB, STN, or PPT stimulation-evoked dopamine efflux were quantified by extraction of 
data points occurring within the range of 0.25 sec pre- and 2.0 sec post-stimulation from 
the recorded oxidation current in the striatum at 30 sec intervals over the course of the 
recording period.  The mean change in dopamine oxidation current, corresponding to 
stimulation-evoked dopamine efflux, was converted to a mean dopamine concentration 
(µM) by post-experiment in vitro calibration of the carbon fiber electrode in solutions of 
dopamine (2-10 µM) using a flow injection system (Michael and Wightman, 1999).  For 
each animal, changes in stimulation-evoked dopamine concentration after infusion were 
expressed as mean percent changes with respect to pre-infusion baseline responses 
(100%).  Mean peak levels in dopamine concentration following the infusion were 
statistically compared to pre-infusion baseline responses using paired two-tailed t-tests 
with the alpha level set at 0.05. 
 
Histology 
Upon the completion of each experimental session, an iron deposit was made in the 
stimulation and recording site by passing direct anodic current (100 μA and 1 mA, 
respectively) for 10 sec through the stimulating and recording electrodes, and 1.0 µl 
cresyl violet stain was infused into the cannula site.  Mice were then euthanized with a 
0.25 ml intracardial injection of urethane (0.345 g/ml).  Brains were removed, immersed 
overnight in 10% buffered formalin containing 0.1% potassium ferricyanide, and then 
stored in 30% sucrose/ 10% formalin solution until sectioning.  After fixation, 30 µm 
coronal sections were sliced in a cryostat at -30°C, with a Prussian blue spot resulting 
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from a redox reaction of the ferricyanide marking the stimulation site.  Placements of 
stimulating electrodes, recording electrodes, and drug infusion cannulae were determined 




Urethane, lidocaine, kynurenate, MCPG, scopolamine, and mecamylamine were obtained 
from Sigma-Aldrich Chemical Co. (St Louis, MO, USA).  All chemicals, with the 
exception of urethane (distilled water), were dissolved in sterile PBS (pH~7.4). 
 
Results 
Stereotaxic placements of infusion cannulae, recording and stimulating electrodes 
Recording electrode placements (n = 56) were confined to the striatum (range in mm: 
1.34 to 1.54 anterior to bregma, 1.30 to 1.60 lateral to midline, and 2.40 to 2.70 ventral to 
dura; Fig. 1A).  Stimulating electrode tips (n = 20) were localized within the MFB (range 
in mm: 1.94 to 2.18 mm posterior to bregma, 1.00 to 1.20 mm lateral to midline, and 3.80 
to 4.10 mm ventral to dura; Fig. 1B).  Stimulating electrode tips (n = 28) and infusion 
cannula tip placements (n = 16) were accurately positioned within the STN (range in mm: 
1.94 to 2.18 posterior to bregma, 1.50 to 1.70 lateral to midline, and 3.90 to 4.20 ventral 
to dura; Fig. 1B), and infusion cannula tip placements (n = 28) were localized within the 
SNc (range in mm: 2.92 to 3.16 posterior to bregma, 1.40 to 1.60 lateral to midline, and 
3.60 to 3.90 ventral to dura; Fig. 1C).  The tips of stimulating electrodes (n = 24) and 
infusion cannula (n = 8) were confined within the PPT (range in mm: 0.39 to 0.63 
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posterior to lambda, 1.15 to 1.40 lateral to midline, and 2.60 to 2.90 ventral to dura; Fig. 




Fig. 1.  Representative coronal sections of the mouse brain (adapted from the atlas of 
Paxinos and Franklin, 2001), with dark gray shaded areas indicating the placements of 
carbon fiber recording electrodes in the striatum (A), stimulating electrodes or drug 
infusion cannulae in the medial forebrain bundle (MFB) (B), subthalamic nucleus (STN) 
(B), substantia nigra compacta (SNc) (C), or pedunculopontine tegmental nucleus (PPT) 







Effects of intra-SNc or PPT lidocaine or SNc GluR blockade on MFB stimulation-evoked 
dopamine efflux 
With respect to pre-infusion baseline levels, MFB stimulation-evoked striatal dopamine 
efflux was not significantly altered at 5 min following PBS infusion into the SNc (n = 4; 
98.1% ± 0.8, p = 0.09; Fig. 2A and C) or PPT (n = 4; 97.4% ± 1.1, p = 0.10; Fig. 2B and 
D).  Intra-SNc infusion of lidocaine significantly increased MFB stimulation-evoked 
striatal dopamine levels from pre-infusion baseline levels (n = 4; 161.6% ± 12.4, p = 
0.03; Fig. 2A and C) with the peak increase occurring 5 min post-infusion.  However, 
lidocaine infused into the PPT did not significantly alter MFB stimulation-evoked 
dopamine efflux in the striatum assessed at 5 min following infusion (n = 4; 95.8% ± 3.9, 
p = 0.35; Fig. 2B and D).  Infusion of the iGluR antagonist kynurenate into the SNc also 
had no significant affect on MFB stimulation-evoked striatal dopamine efflux assessed at 






Fig. 2.  Mean amperometric recordings of dopamine release in the striatum evoked by 
electrical stimulation of the dorsal portion of the medial forebrain bundle (A and B) and 
corresponding mean peak percentages (C and D).  Profiles illustrate mean peak effects in 
response to substantia nigra compacta (SNc) (A) or pedunculopontine tegmental nucleus 
(PPT) (B) microinfusions of sterile phosphate-buffered saline (PBS, pH~7.4) or lidocaine 
(lid) or the ionotropic glutamate receptor antagonist kynurenate (kyn).  Time zero 
indicates the start of the train of 20 pulses at 50 Hz.  * Significant change in striatal 






Effects of intra-SNc or PPT lidocaine on STN stimulation-evoked dopamine efflux 
With respect to pre-infusion baseline levels, STN stimulation-evoked striatal dopamine 
efflux was not significantly altered at 5 min following PBS infusion into the SNc (n = 4; 
96.2% ± 1.7, p = 0.11; Fig. 3A and C) or PPT (n = 4; 99.5% ± 3.1, p = 0.87; Fig. 3B and 
D).  STN stimulation-evoked striatal dopamine efflux was significantly attenuated by 
lidocaine (4%) infused into either the SNc (n = 4; 15.9% ± 3.9, p < 0.01; Fig. 3A and C) 
or the PPT (n = 4; 54.2% ± 6.4, p = 0.02; Fig. 3B and D) compared to pre-infusion 




Fig. 3.  Mean amperometric recordings of dopamine release in the striatum evoked by 
electrical stimulation of the subthalamic nucleus (A and B) and corresponding mean peak 
percentages (C and D).  Profiles illustrate mean peak effects in response to substantia 
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nigra compacta (SNc) (A) or pedunculopontine tegmental nucleus (PPT) (B) 
microinfusions of sterile phosphate-buffered saline (PBS, pH~7.4) or lidocaine (lid).  
Time zero indicates the start of the train of 20 pulses at 50 Hz.  * Significant change in 




Effects of SNc GluR or AchR blockade on STN stimulation-evoked dopamine efflux 
With respect to pre-infusion baseline levels, intra-SNc infusion of the iGluR antagonist 
kynurenate (1 µg) significantly attenuated STN stimulation-evoked striatal dopamine 
levels (n = 4; 54.1% ± 3.0, p < 0.01; Fig. 4A and B) with the peak decrease occurring 5 
min post-infusion; however, intra-SNc infusion of the mGluR antagonist MCPG (1 µg) 
had no significant effect on STN stimulation-evoked striatal dopamine levels (n = 4; 
97.1% ± 1.1, p = 0.09; Fig. 4A and B).  STN stimulation-evoked striatal dopamine was 
also significantly reduced by intra-SNc infusion of the muscarinic AchR antagonist 
scopolamine (10 µg; n = 4; 72.2% ± 4.6, p < 0.01; Fig. 4A and B) or the nicotinic AchR 
antagonist mecamylamine (1 µg; n = 4; 71.8% ± 4.8, p = 0.01; Fig. 4A and B), with the 






Fig. 4.  Mean amperometric recordings of dopamine release in the striatum evoked by 
electrical stimulation of the subthalamic nucleus (A) and corresponding mean peak 
percentages (B).  Profiles illustrate mean peak effects in response to substantia nigra 
compacta (SNc) microinfusions of the ionotropic glutamate receptor antagonist 
kynurenate (kyn), the metabotropic glutamate receptor antagonist (+)-methyl-4-
carboxyphenylglycine (MCPG), the muscarinic acetylcholine receptor antagonist 
scopolamine (scop), or the nicotinic acetylcholine receptor antagonist mecamylamine 
(mec).  Time zero indicates the start of the train of 20 pulses at 50 Hz.  * Significant 
change in striatal dopamine concentration after infusion compared to pre-infusion 






Effects of intra-SNc or STN lidocaine on PPT stimulation-evoked dopamine efflux 
With respect to pre-infusion baseline levels, PPT stimulation-evoked striatal dopamine 
efflux was not significantly altered at 5 min following PBS infusion into the SNc (n = 4; 
98.2% ± 2.2, p = 0.50; Fig. 5A and C) or STN (n = 4; 95.7% ± 3.3, p = 0.28; Fig. 5B and 
D).  PPT stimulation-evoked dopamine in the striatum was completely abolished 
following intra-SNc lidocaine (4%) infusion (n = 4; 9.9% ± 2.6, p < 0.01; Fig. 5A and C) 
and significantly, but less dramatically, reduced following intra-STN lidocaine infusion 
(n = 4; 50.0% ± 7.7, p < 0.01; Fig. 5B and D), with the peak decrease at each site 




Fig. 5.  Mean amperometric recordings of dopamine release in the striatum evoked by 
electrical stimulation of the pedunculopontine tegmental nucleus (A and B) and 
corresponding mean peak percentages (C and D).  Profiles illustrate mean peak effects in 
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response to substantia nigra compacta (SNc) (A) or subthalamic nucleus (STN) (B) 
microinfusions of sterile phosphate-buffered saline (PBS, pH~7.4), lidocaine (lid), a 
combination of the ionotropic glutamate receptor antagonist kynurenate (kyn) with the 
metabotropic glutamate receptor antagonist (+)-methyl-4-carboxyphenylglycine (MCPG), 
or a combination of the nicotinic acetylcholine receptor antagonist mecamylamine (mec) 
and the muscarinic acetylcholine receptor antagonist scopolamine (scop).  Time zero 
indicates the start of the train of 20 pulses at 50 Hz.  * Significant change in striatal 
dopamine concentration after infusion compared to pre-infusion baseline responses 
(100%).   
 
 
Effects of STN GluR or AchR blockade on PPT stimulation-evoked dopamine efflux 
With respect to pre-infusion baseline levels, infusion of a combination of the iGluR 
antagonist kynurenate (1 µg) and the mGluR antagonist MCPG (1 µg) into the STN 
significantly attenuated PPT stimulation-evoked dopamine efflux in the striatum (n = 4; 
77.5% ± 6.2, p = 0.03; Fig. 5B and D) with the peak decrease occurring 5 min post-
infusion.  PPT stimulation-evoked striatal dopamine was also significantly reduced by 
blockade of STN AchRs (n = 4; 74.2% ± 3.4, p < 0.01; Fig. 5B and D) via infusion of a 
combination of the mAchR antagonist scopolamine (10 µg) and the nAchR antagonist 







As measured by in vivo FPA, stimulation of either the MFB, STN, or PPT elicits 
dopamine release in the dorsal striatum.  STN stimulation-evoked striatal dopamine 
release was markedly attenuated by inactivation of either the SNc or the PPT, and PPT 
stimulation-evoked dopamine release in the striatum was significantly reduced following 
inactivation of either the SNc or the STN.  Therefore, neural interactions between these 
nuclei are likely involved in the underlying mechanisms of DBS as a treatment for the 
motor symptoms of Parkinson’s disease.  The present findings provide a glimpse at the 
relative significance of the glutamatergic and cholinergic connections between the SNc, 
STN, and PPT in regards to striatal dopamine neurotransmission.  
 
Neuronal pathways mediating striatal dopamine release following MFB stimulation 
Lee et al. (2006) used a monoclonal antibody to TH to demononstrate in rats that the 
axons of ascending dopamine neurons from the SNc align closely along the dorsal 
surface of the STN with some fibers potentially passing through the nucleus itself.  A 
similar pattern of TH staining of catecholaminergic neurons has been shown in both 
monkeys and humans (Lee et al., 2005).  Thus, it is conceivable that clinical DBS of the 
STN is activating these axons of the MFB due to the close proximity and that HFS of the 
MFB may optimally enhance dopamine transmission in the basal ganglia (Lee et al., 
2006).  The present findings suggest that MFB stimulation is mediated predominately by 
activation of ascending SNc dopamine neurons, as lidocaine infusions into the SNc did 
not reduce MFB-evoked striatal dopamine release.  Previous studies have shown that 
pharmacological denervation of dopamine axonal transmission promotes a rapid 
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compensatory mechanism that dramatically enhances synthesis and storage of dopamine 
in terminal vesicles (Brown et al., 1991).  These findings are consistent with our 
observation of an enhancement in MFB stimulation-evoked striatal dopamine release 
following lidocaine inactivation of the SNc.  The present results show that stimulation of 
the MFB is not dependent upon SNc iGluRs, as kynurenate infused into the SNc had no 
effect on MFB-evoked dopamine, again suggesting that MFB stimulation is mediated 
predominately by activation of ascending SNc dopamine neurons rather than 
neurochemical activities within the SNc.  Altogether, these data may help to explain the 
clinical improvements in motor symptoms of Parkinson’s patients following stimulation 
of the border and white matter dorsal to the STN (Herzog et al., 2004; Saint-Cyr et al., 
2002; Voges et al., 2002). 
 
Neuronal pathways mediating striatal dopamine release following STN stimulation 
The present study examined several neuronal circuits in the mid- and hindbrain by which 
clinical DBS of the STN could increase striatal dopamine transmission.  Stimulation of 
the STN has been shown to alter neuronal activity within the SNc of rodents generating 
initial transient inhibitory (via activation of GABAergic interneurons in the SN reticulata) 
and more prolonged excitatory (via direct activation of dopaminergic neurons in the SNc) 
postsynaptic potentials (Lee et al., 2004), leading to increased firing of SNc neurons 
(Hammond et al., 1978; Iribe et al., 1999; Benazzou et al., 2000).  Changes in STN 
activity have also been shown to significantly affect discharge patterns of SNc neurons 
and striatal dopamine release in primates.  Shimo and Wichmann (2009) concluded that 
increases in the firing rate of SNc neurons following intra-STN injections of carbachol, 
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and decreases in the firing rate of SNc neurons after intra-STN injections of muscimol, 
may have resulted from changes in activity along the connections between the STN and 
SNc via an excitatory glutamatergic pathway well documented in rodent research 
(Hammond et al., 1978; Kita and Kitai, 1987; Smith and Parent, 1988).  However, the 
monosynaptic pathway between the STN and SNc has been shown to be relatively sparse 
in primates compared to rodents (Smith et al., 1990; Sato et al., 2000).  Therefore, the 
observed changes in SNc discharge patterns in primates may have been mediated 
primarily by excitatory SNc afferents from the PPT (Futami et al., 1995; Charara et al., 
1996).  The STN and PPT are reciprocally interconnected with excitatory projections 
(Futami et al., 1995; Lee et al., 2000), which have been shown to be both cholinergic and 
glutamatergic from the PPT to the STN (Moon-Edley and Graybiel, 1983; Oakman et al., 
1999).  In vivo electrochemical studies in rodents have previously shown that electrical 
and chemical stimulation of the PPT enhances dopamine efflux in the striatum (Forster 
and Blaha, 2003; Miller and Blaha, 2004); thus, it is highly probable that stimulation of 
the STN in primates may be increasing discharge patterns of SNc dopaminergic neurons 
to elicit striatal dopamine release indirectly through STN activation of the PPT.   
 The present results confirm that STN stimulation is dependent on activities of 
both the SNc and PPT, as inactivation of either of these nuclei decreased STN-evoked 
striatal dopamine efflux by 84.1% and 45.8%, respectively, compared to pre-infusion 
baseline responses.  Thus, these findings suggest that HFS of the STN works by 
activating the SNc directly via excitatory STN-SNc projections and indirectly via 
excitatory STN-PPT projections that, in turn, provide excitatory PPT inputs to SNc 
dopamine cells.  However, these findings cannot distinguish the extent to which STN 
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stimulation is activating dopamine cells in the SNc via reciprocal excitatory innervation 
between the STN and PPT.  Future experiments incorporating intra-STN infusions of 
selective glutamate and acetylcholine receptor antagonists would address this issue.  In 
addition, STN stimulation-evoked striatal dopamine release was significantly diminished 
by inactivation of the SNc; however, it was not completely abolished.  This is not 
surprising considering the relatively wide medial to lateral distribution of dopamine cell 
bodies in the midbrain comprising the SNc (see Fig. 1C), such that a single infusion of 
drug into the SNc likely fails to inactivate all of these cells.  Thus, the small remaining 
response (15.9%) can be attributed either to incomplete drug inactivation of the SNc.  
Alternatively, unavoidable stimulation of some of the dopamine axons within the medial 
forebrain bundle that project immediately dorsal to STN on their way to the striatum may 
also have contributed to the response following intra-SNc lidocaine inactivation.  This 
observation would support the notion that STN DBS may act by directly stimulating SNc 
dopamine axons passing near or through the STN (Lee et al., 2006).  
The STN and PPT are the only subcortical nuclei in the basal ganglia complex 
whose glutamate-containing neurons directly innervate nigrostriatal dopaminergic 
neurons (Kitai et al., 1999; Overton and Clark, 1997).  Stimulation of the STN has been 
shown to alter neuronal activity within the substantia nigra of rodents resulting in 
elevated glutamate release in the SNc (Windels et al., 2000).  Glutamate release in the 
SNc activates dopamine neurons that project to the striatum.  The present results show 
that STN stimulation is dependent upon iGLuRs, but not mGluRs, in the SNc as intra-
SNc kynurenate significantly decreased STN-evoked striatal dopamine release (54.1%) 
while intra-SNc MCPG had no effect.  These findings are consistent with our previous 
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findings and others (Balon et al., 2003; Forster and Blaha, 2003; Lavoute et al., 2006).  
The remaining STN stimulation-evoked striatal dopamine release (45.9%) following 
intra-SNc kynurenate infusion can be attributed to a major extent to excitatory 
cholinergic SNc inputs from the PPT.  However, as mentioned, it cannot be completely 
discounted that a small portion of the signal may have been due to unavoidable 
stimulation of a small number of dopamine axons immediately dorsal to the STN within 
the medial forebrain bundle.  Intra-SNc infusions of scopolamine or mecamylamine 
decreased STN-evoked striatal dopamine release by 27.8% and 28.2%, respectively.  
Accordingly, these results suggest that cholinergic projections from the PPT to the SNc 
mediate roughly half of the STN stimulation-evoked dopamine release in the striatum.  In 
sum, the present data confirms the significance of the PPT in STN stimulation-evoked 
striatal dopamine release and suggest that glutamatergic projections (acting on iGluRs in 
the SNc) and cholinergic projections (acting on mAchRs and nAchRs in the SNc) 
mediate approximately half of the striatal dopamine release following STN stimulation. 
 
Neuronal pathways mediating striatal dopamine release following PPT stimulation 
Excitatory glutamatergic and cholinergic inputs from the PPT directly project to 
dopamine-containing cell bodies in the SNc (Blaha and Winn, 1993; Forster and Blaha, 
2003; Moon-Edley and Graybiel, 1983; Oakman et al., 1999).  Our previous work using 
in vivo chronoamperometry to measure basal changes in dopamine release has shown that 
PPT stimulation elicits an initial transient increase in striatal dopamine release, in which 
this rapid increase in dopamine release could be blocked by a combination of intra-SNc 
infusions of nAchR and iGluR antagonists.  This transient stimulation time-locked 
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increase was followed by a delayed, prolonged increase in striatal basal dopamine release 
that could be selectively blocked by mAchR antagonists infused into the SNc (Forster 
and Blaha, 2003).  However, electrical stimulation of the PPT has also been shown to 
activate STN neurons via cholinergic and glutamatergic projections (Woolf and Butcher, 
1986; Hammond et al., 1983).  Therefore, in addition to direct cholinergic activational 
inputs to SNc dopaminergic cells, the PPT may also enhance striatal dopamine release via 
indirect PPT glutamatergic and cholinergic inputs to STN glutamatergic neurons that, in 
turn, innervate directly dopamine-containing cells in the SNc (Bevan and Bolam, 1995; 
Lee et al., 2000).  The present results show that PPT stimulation-evoked striatal 
dopamine release is significantly dependent on activities of the SNc and STN, as 
inactivation of the SNc and STN lead to decreases in PPT-evoked striatal dopamine 
efflux of 90.1% and 50.0%, respectively, compared to pre-infusion baseline responses.  
Thus, these findings suggest that clinical DBS of the PPT may involve activation of the 
SNc directly via excitatory PPT-SNc projections and indirectly via excitatory PPT-STN 
projections that, in turn, provide excitatory inputs to SNc dopamine cells.  However, 
these findings cannot distinguish the extent to which PPT stimulation is activating 
dopamine cells in the SNc via reciprocal excitatory innervation between the STN to the 
PPT.  Future experiments incorporating intra-PPT infusions of selective GluR antagonists 
would address this issue. 
The present study further examined the excitatory glutamatergic and cholinergic 
pathway from the PPT to the STN and found that PPT-evoked striatal dopamine release is 
dependent upon both GluRs and AchRs in the STN, as intra-STN GluR antagonists or 
AchR antagonists both significantly decreased PPT-evoked striatal dopamine release by 
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22.5% or 25.8%, respectively.  Together, the present data confirms the significance of the 
SNc, as well as the STN, in PPT stimulation-evoked striatal dopamine release and 
suggests that combined glutamatergic and cholinergic projections from the PPT to the 
STN are mediate approximately half of PPT-evoked dopamine release in the striatum. 
 
Conclusions 
The present study shows that electrical stimulation of the MFB, STN, or PPT elicits 
dopamine release in the striatum.  MFB stimulation evokes striatal dopamine through 
direct stimulation of dopamine axons and is independent of neurochemical activity within 
the SNc and PPT, while STN or PPT stimulation elicits striatal dopamine through several 
neural routes.  The relative contributions of the direct and indirect projections to the SNc 
that are involved in mediating STN or PPT stimulation-evoked dopamine release are 
summarized in Fig. 6A and B.  STN-evoked dopamine release in the striatum is almost 
fully dependent upon (84.1%) activation of dopamine cells in the SNc, while also 
partially dependent upon projections from the PPT (45.9%).  Fig. 6A also illustrates the 
relative involvement of SNc iGluRs (45.9%) and mAchRs and nAchRs (27.8% and 
28.2%, respectively) in STN-evoked striatal dopamine release.  PPT-evoked striatal 
dopamine release was highly dependent upon activation of dopamine cells in the SNc 
(90.1%), and partially dependent upon activation of STN cells that project to the SNc 







Fig. 6.  Summary of relative contributions of neuronal projections mediating subthalamic 
nucleus (STN) (A) or pedunculopontine tegmental nucleus (PPT) (B) stimulation-evoked 
dopamine release in the striatum (stri).  ACh: acetylcholine; Glu: glutamate; m/nAchR: 
muscarinic/nicotinic acetylcholine receptor; iGluR: ionotropic glutamate receptor; SNc: 
substantia nigra compacta.   
 
 
  In relation to DBS as a treatment for Parkinson’s disease, these findings support 
research indicating that DBS of the STN, as well as the PPT, provides therapeutic 
benefits due to increased extracellular levels of dopamine in the striatum (Lee et al., 
2009).  Although these studies were conducted in intact animals, future experiments 
using the present neurochemical recording procedures in 6-OHDA lesioned mice would 
provide knowledge of the involvement of these pathways in an animal model of 
Parkinson’s disease.  Another intriguing future experiment could be monitoring 
dopamine concentrations while stimulating the STN and PPT simultaneously, as clinical 
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studies have shown combined STN and PPT DBS to be more therapeutically efficacious 
than DBS of the STN or PPT alone on certain symptoms, such as the control of axial 
motor impairments (Stefani et al., 2007).  Understanding the underlying mechanisms of 
DBS of the STN and the interconnected PPT could lead to improvements in stimulation 
locations and parameters, which may prove invaluable in improving DBS procedures and 
enhancing its clinical efficacy for the treatment of Parkinson’s disease. 
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Chapter 6. Substantia Nigra Compacta Glutamate Receptors Modulate 
Dopamine Release in the Striatum 
 
The nigrostriatal dopamine pathway, comprised of dopamine-containing neurons in the 
substantia nigra compacta (SNc) and their projections to the striatum, is integral in motor 
functioning, including the selection and initiation of contextually appropriate motor 
patterns (Hauber, 1998; Redgrave et al., 1999).  The dopaminergic neurons of the SNc 
degenerate in Parkinson’s disease, leading to reduced dopamine levels in the striatum 
and, subsequently, clinical symptoms such as bradykinesia, tremor, and rigidity (Fearnley 
and Lees, 1991; Olanow and Tatton, 1999).  Identifying receptors that modulate the 
activity of dopamine neurons in the SNc may help in the development of novel 
therapeutic strategies for treating the symptoms of Parkinson’s disease and perhaps even 
slowing the progression of the disease.  The subthalamic nucleus (STN) and the 
pedunculopontine tegmental nucleus (PPT) provide significant glutamatergic excitatory 
inputs to the SNc, which induce burst firing of SNc dopamine neurons resulting in 
sustained release of dopamine in the striatum (Grillner and Mercuri, 2002; Kitai et al, 
1999; Overton and Clark, 1997).  Glutamatergic input to the SNc has received a great 
deal of attention based on findings that suggest overactivity of STN glutamatergic 
projections in Parkinson’s disease and the potential contributory role of long-lasting 
glutamate receptor stimulation in the degeneration of dopaminergic neurons (Rodriguez 
et al., 1998).  The present study expands on the involvement of these projections in 




Previous studies have shown that the effects of glutamate in the SNc are mediated 
by ionotropic glutamate receptors (iGluRs), which activate ion-gated channels, and 
metabotropic glutamate receptors (mGluRs), which activate slow and more complex 
effects mediated by G-coupled protein secondary messenger systems (Chatha et al, 2000; 
Valenti et al, 2005).  Three iGluR subclasses have been identified based on their 
definitive agonist and include N-methyl-D-aspartic acid (NMDA), -amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA), and kainate, with the latter 2 sometimes 
collectively referred to as non-NMDA receptors (Hollmann and Heinemann, 1994).  The 
relative contribution of these glutamate receptor subtypes in the SNc in mediating STN 
glutamatergic activation of fast phasic activity of the nigrostriatal dopamine system 
remains largely unknown.  Therefore, the present study investigated the extent to which 
each of these GluR subtypes is involved in mediating striatal dopamine release by 
infusing NMDA, AMPA/kainate, and mGluR antagonists into the SNc while recording 
STN stimulation-evoked dopamine efflux in the striatum using in vivo fixed potential 
amperometry with carbon fiber microelectrodes.   
 
Experimental procedures 
All experiments were approved by the Institutional Animal Care and Use Committee at 
the University of Memphis and conducted in accordance with the NIH Guidelines for the 
Care and Use of Laboratory Animals.  Efforts were made to reduce the number of 





Animals and surgery 
Sixteen male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA), 8-11 weeks 
of age and weighing 20-27 g at the time of surgery, were used. Mice were housed four 
per cage at 21 ± 1ºC with a 12 h light: 12 h dark cycle (lights on at 0600 h).  Food and 
water were available ad libitum.  Mice were anesthetized with urethane (1.5 g/kg, i.p.) 
and mounted in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) with a 
mouse head-holder adaptor (Stoelting, Wood Dale, IL, USA).  A temperature-regulated 
heating pad (TC-1000; CWE Inc., New York, NY, USA) maintained body temperature at 
36 ± 0.5°C.  All stereotaxic coordinates (AP from bregma, ML from midline, and DV 
from dura, in mm) were determined from the mouse atlas of Paxinos and Franklin (2001).  
In each mouse, a concentric bipolar stimulating electrode (SNE-100; Rhodes Medical 
Co., CA, USA) was implanted into the left STN (coordinates: AP -2.0, ML +1.6, DV -
4.0).  A 31 g stainless-steel guide infusion cannula was implanted into the left SNc, with 
the guide cannula tip 2 mm above site (coordinates: AP -3.1, ML +1.5, DV -3.8).  An 
Ag/AgCl reference and stainless-steel auxiliary electrode combination was placed on 
contralateral cortical tissue approximately 2.0 mm posterior to bregma, and a carbon fiber 
recording electrode (250 μm length x 10 μm o.d.; Thornel Type P, Union Carbide, 
Pittsburgh, PA, USA) was then implanted into the left striatum (coordinates: AP 1.4, 
ML +1.4, DV -2.5).  
 
Fixed potential amperometry and electrical stimulation 
Amperometric recordings in a Faraday cage consisted of applying a fixed potential (+0.8 
V) to the recording electrode and monitoring dopamine oxidation current continuously 
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(10K samples/sec) with an electrometer filtered at 50 Hz.  Approximately 10 min 
following implantation of the electrodes, a series of 0.5 ms duration cathodal monophasic 
current pulses (20 pulses at 50 Hz applied every 30 sec at 800 µAmps) was delivered to 
the stimulating electrode via an optical isolator and programmable pulse generator (Iso-
Flex/Master-8; AMPI, Jerusalem, Israel).  Fixed potential amperometry with carbon fiber 
electrodes has been confirmed as a valid technique for real-time monitoring of changes in 
striatal dopamine oxidation current evoked by electrical stimulation of afferent inputs to 




Intra-SNc infusions were performed by backloading each drug into a fibreglass cannula 
(80 m o.d., Polymicro Tech. Inc., AZ, USA) connected via PE10 tubing to a 5 l 
microsyringe (Scientific Glass Engineering Inc., Austin, TX, USA) mounted on a 
microinfusion pump (Stoelting, Wood Dale, IL, USA).  After a 10 min baseline recording 
period, the cannula was inserted 2 mm beyond the guide cannula tip, and 1.0 µl infusions 
were made over a 1.5 min period.  Separate groups of mice received intra-SNc infusions 
of the following drugs: the mGluR antagonist (+)-α-methyl-4-carboxyphenylglycine 
(MCPG) (2.0 µg), the NMDA receptor antagonist (±)-3-(2-carboxypiperazin-4-yl)-
propyl-1-phosphonic acid (CPP) (1.0 µg), and the AMPA/kainate receptor antagonist 6-
cyano-7-1fitroquinoxaline-2,3-dione (CNQX) (0.2 µg).  Drugs were prepared 
immediately before use at doses determined by preliminary studies in this laboratory.  
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Separate phosphate-buffered saline (PBS, pH~7.4) infusions served as drug effect 
controls. 
 
Data collation and statistical analysis 
STN stimulation-evoked dopamine efflux were quantified by extraction of data points 
occurring within the range of 0.25 sec pre- and 2.0 sec post-stimulation at 30 sec intervals 
from the recorded oxidation current.  Mean changes in striatal dopamine oxidation 
current, corresponding to STN stimulation-evoked dopamine efflux, were converted to 
mean dopamine concentrations (µM) by post-experiment in vitro calibration of the 
carbon fiber electrode in solutions of dopamine (2-10 µM) using a flow injection system 
(Michael and Wightman, 1999).  For each animal, changes in stimulation-evoked 
dopamine concentration after infusion were expressed as mean percent changes with 
respect to pre-infusion baseline responses (100%).  Mean peak levels in dopamine 
concentration following the infusion were statistically compared to pre-infusion baseline 
responses using paired two-tailed t-tests.  In order to compare the relative contributions of 
NMDA and AMPA/kainate SNc receptors, mean peak percentage changes in dopamine 
concentration were compared between the mice receiving intra-SNc infusion of CPP and 
those receiving intra-SNc CNQX using independent two-tailed t-tests.  The alpha level 
for all analyses was set at 0.01. 
 
Histology 
At the end of each experiment, an iron deposit was made by passing direct anodic current 
(100 μA for 10 sec) through the stimulating and recording electrodes, and 1.0 µl cresyl 
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violet stain was infused through the cannula.  Mice were then euthanized with a 0.25 ml 
intracardial injection of urethane (0.345 g/ml).  Brains were removed, immersed 
overnight in 30%/10% sucrose/formalin plus 0.1% potassium ferricyanide until 
sectioning.  After fixation, 30 µm coronal sections were sliced in a cryostat at -30°C, and 
placements of stimulating electrodes, recording electrodes, and drug infusion cannulae 
were determined under a light microscope and recorded on representative coronal 
diagrams (Paxinos and Franklin, 2001). 
 
Chemicals 
Urethane, CPP, CNQX, and MCPG were obtained from Sigma-Aldrich Chemical Co. (St 
Louis, MO, USA).  All chemicals, with the exception of urethane (distilled water), were 
dissolved in sterile PBS (pH~7.4). 
 
Results 
Stereotaxic placements of infusion cannulae, recording and stimulating electrodes 
Recording electrode placements (n = 16) were confined to the dorsal striatum (range in 
mm: 1.34-1.54 anterior to bregma; 1.30-1.60 lateral to midline; 2.40-2.70 ventral to dura) 
(Fig. 1A).  Stimulating electrode tips (n = 16) were positioned within the STN (range in 
mm: 1.94-2.18 posterior to bregma; 1.50-1.70 lateral to midline; 3.90-4.20 ventral to 
dura) (Fig. 1B).  Cannula tip placements (n = 16) were localized within the SNc (range in 
mm: 2.92-3.16 posterior to bregma; 1.40-1.60 lateral to midline; 3.60-3.90 ventral to 





Fig. 1.  Representative coronal sections of the mouse brain (adapted from the atlas of 
Paxinos and Franklin, 2001), with shaded areas indicating the placements of (A) 
amperometric recording electrodes in the striatum, (B) stimulating electrodes in the 
subthalamic nucleus (STN), (C) drug infusion cannulae in the substantia nigra compacta 
(SNc). Numbers correspond to mm from bregma. 
 
 
Effects of GluR blockade on STN stimulation-evoked dopamine efflux  
Intra-SNc infusion of PBS (n = 4) did not significantly alter STN stimulation-evoked 
striatal dopamine efflux from pre-infusion baseline levels (96.2% ± 1.7 at 5 min post-
infusion, p = 0.110) (Fig. 2A and B).  Infusion of the mGluR antagonist MCPG (2.0 µg; n 
= 4) also had no significant effect on STN-evoked striatal dopamine efflux (97.1% ± 1.1 
at 5 min post-infusion, p = 0.084) (Fig. 2A and B).  However, intra-SNc infusion of the 
NMDA receptor antagonist CPP (1.0 µg; n = 4) or the AMPA/kainate receptor antagonist 
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CNQX (0.2 µg; n = 4) significantly decreased evoked dopamine efflux, reaching a 
maximum of 60.1% ± 5.2 and 67.6% ± 2.3 respectively (p < 0.01) at 5 min post-infusion 
(Fig. 2A and B).  The peak percent change of STN stimulation-evoked dopamine striatal 
release following intra-SNc CPP were not significantly different compared to the percent 




Fig. 2.  Mean amperometric recordings of dopamine release in the striatum evoked by 
electrical stimulation of the subthalamic nucleus (A) and corresponding mean peak 
percentages (B) following substantia nigra compacta (SNc) microinfusions of phosphate-
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buffered saline (PBS, pH~7.4), the metabotropic glutamate receptor antagonist (+)-
methyl-4-carboxyphenylglycine (MCPG), the NMDA receptor antagonist (±)-3-(2-
carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP), the AMPA/kainate receptor 
antagonist 6-cyano-7-1fitroquinoxaline-2,3-dione (CNQX).  Time zero indicates the start 
of the stimulation (20 pulses at 50 Hz).  * Significant change in striatal dopamine 
concentration after infusion compared to pre-infusion baseline responses (100%). 
 
Discussion  
STN stimulation-evoked dopamine release in the striatum as measured using in vivo fixed 
potential amperometry was significantly attenuated following infusion of an NMDA or 
AMPA/kainate antagonist into the SNc. In contrast, intra-SNc infusion of an mGluR 
antagonist, including drug vehicle (PBS), had no effect on STN stimulation-evoked 
dopamine release in the striatum.  The present results suggest that iGluRs in the SNc, 
compared to mGluRs, play a more critical role in mediating relatively brief excitatory 
glutamatergic activation of SNc dopamine neurons.  
 
The role of SNc mGluRs in mediating nigrostriatal dopamine activity 
The present finding that intra-SNc MCPG had no effect on STN stimulation-evoked 
dopamine release in the striatum warrants consideration.  The mGluRI subtype, 
belonging to the Group I mGluRs, is the predominant mGluR subtype localized to SNc 
dopamine cells (Kosinski et al., 1998; Testa et al., 1994), justifying the use of the Group I 
and II antagonist MCPG (Pin and Duvoisin, 1995; Riedel, 1996).  Furthermore, we 
utilized a dose of MCPG that has been effective in abolishing accumbal basal dopamine 
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efflux as evoked by electrical stimulation of the ventral subiculum of the hippocampus 
(Blaha et al., 1997).  Consequently, the results of the present study imply that mGluRs in 
the SNc are not employed by STN glutamatergic afferents to mediate striatal dopamine 
efflux.  Previous studies on the role of SNc mGluR receptors in nigrostriatal dopamine 
activity are somewhat conflicting.  The activation of mGluR1 subtype in the SNc has 
been shown to both excite and inhibit dopamine neurons (Fiorillo and Williams, 1998; 
Guatteo et al, 1999; Meltzer et al., 1997), while the activation of Group II mGluRs at 
STN-SNc synapses, most likely located presynaptically on glutamatergic terminals, 
inhibits glutamatergic transmission in SNc dopamine neurons (Bonci et al, 1997; Wang et 
al., 2005).  Our utilization of fixed potential amperometry allows for the measurement of 
phasic dopamine release, rather than basal extracellular levels of dopamine.  Thus, the 
rapid responses seen with STN-stimulation, generating burst firing of SNc dopamine 
neurons, are most likely not affected by the complex, relatively slower, actions of 
mGluRs.  While the findings of the present study are strengthened by similar previous 
findings that intra-SNc MCPG had no effect on brief PPT stimulation-evoked striatal 
dopamine release (Forster and Blaha, 2003), further studies involving various doses of 
MCPG and other mGluR antagonists are needed before the use of mGluRs by STN 
projections to the SNc can be excluded. In this regard, it is significant to note that 
prolonged stimulation of the STN has been shown to result in an initial short duration 
increase in phasic striatal dopamine release (~1 sec) that is followed by a lower but still 
elevated level of dopamine release (Lee et al., 2006).  This later inhibition of stimulation-
evoked phasic dopamine release was thought to reflect compensatory effects at the level 
of the SNc glutamate-containing terminal. Theoretically, activation of group II and III 
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mGluRs on glutamate-containing terminals may attenuate dopamine cell activity by 
reducing excessive glutamate release onto dopamine cells in the SNc, despite a 
continuous level of firing activity (Grillner and Mercuri, 2002; Mercuri et al., 1993). 
 
The role of SNc iGluRs in mediating nigrostriatal dopamine activity 
Both NMDA and non-NMDA receptors were shown to be involved in STN stimulation-
evoked dopamine in the striatum, as evidenced by significantly attenuated responses 
following intra-SNc NMDA or AMPA/kainate receptor antagonists.  The present results 
also indicate that NMDA and AMPA/kainate receptor subtypes have an equal role in 
modulating excitatory glutamatergic inputs arising from the STN, as the maximum 
percent decreases in STN-evoked striatal dopamine release post-infusion did not differ 
between the NMDA and AMPA/kainate receptor antagonists.  Activation of AMPA and 
kainate receptors opens membrane ion-channels to allow the rapid influx of positively 
charged sodium resulting in the generation of fast moment-to-moment excitatory post-
synaptic potentials (Borges and Dingledine, 1998).  NMDA receptors are highly 
conductive to the positive ion calcium, although the entry of calcium in the resting state is 
blocked by magnesium (Chapman, 2009).  Usually, activation of NMDA receptors 
requires colocalised AMPA/kainate receptors to depolarise first so that the entry of 
positive sodium displaces magnesium ions from the NMDA ion pore thus permitting 
calcium influx into the cell, consequently depolarizing it (Michaelis, 1998).  Thus, a 
similar degree of attenuation in STN-evoked striatal dopamine following blockade of 
SNc NMDA or AMPA/kainate receptors in the present study is not surprising.  Previous 
research has shown that synaptic potentials in dopamine neurons evoked by single 
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stimulating pulses are mediated predominantly by activation of AMPA/kainate receptors 
and to a smaller extent through NMDA receptor activation (Johnson and North, 1992; 
Mereu et al, 1991).  Whereas, a preferential role for NMDA receptors, compared to non-
NMDA receptors, in producing burst activity in SNc dopamine neurons has been 
described (Chergui et al., 1994; Overton and Clark, 1997).  It is possible that activation of 
NMDA receptors requires a larger amount of glutamate release than non-NMDA 
receptors, as high frequency stimulation, perhaps corresponding with burst firing, is 
required to evoke synaptic potentials with a large contribution of NMDA receptors 
(Grillner and Mercuri, 2002).  Nonetheless, it seems that glutamatergic excitation of 
dopamine neurons in the SNc, and subsequent striatal dopamine release, is mediated to 
some degree by both NMDA and AMPA/kainate receptors, as widespread distribution of 
both types of these subtype receptors on dopaminergic neurons in the SNc has been well 
established (Chatha et al., 2000).   
 
Conclusions 
The present results suggest that NMDA and AMPA/kainate receptors both play a 
significant role in modulating striatal dopamine release evoked by electrical stimulation 
of the STN.  Because glutamate receptors mediate synaptic transmission in the SNc, a 
vital site in the extrapyramidal motor circuit, pharmacological manipulation of these 
receptors may be able to alter dysfunctional neurotransmission and thus provide a 
promising therapeutic target for treating Parkinson’s disease.  Animal model studies 
suggest that altering the activity of these receptors pharmaceutically may serve to 
alleviate parkinsonian motor symptoms or perhaps even slow disease progression by 
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delaying dopamine neuron degeneration, thought to be associated with excitotoxicity 
caused by relatively high extracellular levels of glutamate.  For example, antagonists of 
NMDA and AMPA receptors have been shown to reverse motor symptoms and 
levodopa-induced dyskinesias in animal models (Gossel et al., 1995; Klockgether and 
Turski, 1990; Schwarz et al., 1996), as would be expected given the findings of the 
present study.  Although blocking SNc mGluRs had no effect on STN stimulation-evoked 
striatal dopamine release in the present study, pharmaceutical modulation of mGluRs 
have shown promise in providing neuroprotection of SNc dopamine neurons in animal 
models of Parkinson’s disease (Johnson et al., 2009), further suggesting a role for 
mGluRs, located presynaptically, in maintaining functional basal glutamate levels in the 
SNc (Grillner and Mercuri, 2002; Mercuri et al., 1993).  Therefore, GluRs represent 
promising targets for the development of nondopaminergic pharmaceutical therapies for 
the treatment of Parkinson’s disease, and more studies are necessary to determine the 
relative contributions of each receptor subtype in mediating afferent activation of the 




 Chapter 7.  Summary, Conclusions, and Implications for Future Research 
 
The experimental studies of Chapters 5 and 6 were undertaken to investigate important 
neural circuits that functionally contribute to phasic dopamine neurotransmission within 
the nigrostriatal dopaminergic system. These investigations were conducted with the 
purpose of extending current knowledge of the neural connectivity of nuclei, specifically 
the substantia nigra compacta (SNc), subthalamic nucleus (STN), and pedunculopontine 
tegmental nucleus (PPT), with projections that mediate striatal dopamine release and 
subsequently influence activity of the basal ganglia-thalamocortical motor circuit.  This 
chapter presents an overview of the present findings and their functional implications to 
pharmaceutical and surgical treatments for the motor symptoms of Parkinson’s disease.   
 Overall, using in vivo fixed potential amperometry the present studies show that 
electrical stimulation of the dorsal portion of the medial forebrain bundle (MFB), STN, or 
PPT, all of which are targets for clinical deep brain stimulation (DBS) procedures as a 
treatment for the motor symptoms of Parkinson’s disease, elicits dopamine release in the 
dorsal striatum.  Stimulation of the MFB, which consists of axons of ascending SNc 
dopamine neurons that project closely along the dorsal surface of the STN to the striatum, 
was investigated as a control for STN stimulation, as it has been suggested that DBS of 
the MFB may optimally enhance dopamine transmission in the basal ganglia, thus 
providing better therapeutic results compared to DBS of the STN (Lee et al., 2006).  The 
present findings confirm that MFB high frequency stimulation (HFS)-evoked striatal 
dopamine release is mediated predominately by activation of ascending SNc dopamine 
neurons, independent of activity within the SNc and PPT.  Striatal dopamine release 
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elicited by STN or PPT stimulation, however, occurs via more complicated neural 
interactions, which are likely involved in the underlying mechanisms of STN or PPT 
DBS as a treatment for the tremor, gait and postural symptoms of Parkinson’s disease.  
Reductions in striatal dopamine release following pharmacological blockade of axonal 
transmission or cholinergic/glutamatergic receptor populations was used to determine  the 
specific involvement of the SNc, STN, and PPT in mediating HFS-evoked striatal 
dopamine release.  The influence of these subcortical nuclei and their intrinsic receptor 
mechanisms on STN or PPT-driven nigrostriatal dopamine transmission is presented 
below. 
 
Subcortical Involvement in STN HFS-Evoked Nigrostriatal Dopamine Transmission 
The present studies examined several neuronal circuits in the mid- and hindbrain that 
could be involved in STN HFS-evoked dopamine release in the striatum.  Results 
confirmed that STN stimulation is dependent on activities of both the SNc and PPT, as 
pharmacological blockade of axonal transmission within either of these nuclei 
significantly decreased STN-evoked striatal dopamine efflux compared to pre-infusion 
baseline responses. Thus, these findings suggest that stimulation of the STN works by 
activating the SNc directly via excitatory STN-SNc projections and indirectly via 
excitatory STN-PPT projections that, in turn, provide excitatory PPT inputs to SNc 
dopamine cells.  The relative contributions of the direct and indirect projections to the 
SNc that are involved in mediating STN HFS-evoked dopamine release are summarized 
in Fig. 1A.  The present data highlight the significance of the PPT in STN HFS-evoked 
striatal dopamine release as neuronal projections through the PPT mediate roughly half 
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(45.9%) of STN HFS-evoked dopamine release in the striatum.   As expected STN-
evoked striatal dopamine release is almost fully dependent upon activation of dopamine 
cells in the SNc; however, blockade of axonal transmission within the SNc did not 
completely abolish STN HFS-evoked striatal dopamine release.  Under the present 
experimental conditions, it is likely that a single infusion of lidocaine or receptor 
blocking drug failed to inactivate the entire SNc, as well as unavoidable stimulation of 
some of the dopamine axons within the MFB that may also have contributed to the 
response elicited by STN stimulation.  It is important to note that in previous 
amperometric recording of STN stimulation-evoked dopamine release in rats (Lee at al., 





Fig. 1.  Summary of relative contributions of neuronal projections mediating subthalamic 
nucleus (STN) (A) and pedunculopontine tegmental nucleus (PPT) (B) HFS-evoked 
dopamine release in the striatum (stri).  ACh: acetylcholine; Glu: glutamate; m/nAchR: 
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muscarinic or nicotinic acetylcholine receptor; iGluR: ionotropic glutamate receptor; 
SNc: substantia nigra compacta. 
 
 
PPT receptor mechanisms mediating STN HFS-evoked nigrostriatal dopamine 
transmission 
Although the present studies only included intra-PPT infusions of lidocaine, rather than 
receptor antagonists, previous studies have shown that the PPT receives glutamatergic 
projections from the STN and prefrontal cortex (Kita and Kitai, 1987; Sesack et al., 
1989), as well as GABAergic projections from the substantia nigra reticulata (SNr) and 
globus pallidus (Kang and Kitai, 1990; Moriizumi and Hattori, 1992).  Both NMDA and 
AMPA receptors have been shown to be located on cholinergic and glutamatergic cells 
within the PPT, and activation of both types of iGluRs increase PPT activation (Steiniger 
and Kretschmer, 2003) (see Fig. 2); however, activation of both A and B GABA receptor 
subtypes has been shown to inhibit activity of PPT neurons, although the precise location 
of these GABA receptors in the PPT remain unclear (Saitoh et al., 2003).  Furthermore, 
mAchRs (specifically of the M2 family) have been localized presynaptically on PPT 
cholinergic neurons (Vilaro et al., 1992).  Intra-PPT infusions of the non-selective 
mAChR antagonist scopolamine enhances striatal dopamine release and dopamine-
dependent behaviors such as locomotion and stereotypy; both of which can be blocked by 
the cholinergic agonist carbachol infused into the PPT (Chapman et al., 1997; Mathur et 
al., 1997). These mAChRs are most likely autoreceptors of the M2 family as intra-PPT 
infusion of the M2/4 selective mAChR antagonist methoctramine has been shown to 
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enhance striatal dopamine release (Miller and Blaha, 2004). Activation of M2-like 
mAChRs in the PPT results in hyperpolarization of mesopontine cholinergic cells 
(Luebke et al., 1993; Leonard and Llinas, 1994) and a net decrease in excitation to SNc 
dopaminergic cells resulting in lowered extracellular levels of striatal dopamine (Forster 
and Blaha, 2003). Therefore, M2-like mAChRs are thought to function as cholinergic 
autoreceptors involved in feedback inhibition at the level of PPT cholinergic cells, 







Fig. 2. Simplified basal ganglia circuitry depicting the muscarinic/nicotinic acetylcholine 
receptors (m/nAchRs), ionotropic/metabotropic glutamate receptors (i/mGluRs), and 
GABA-A/B receptors within the substantia nigra (SN), subthalamic nucleus (STN), and 
pedunculopontine tegmental nucleus (PPT) responsible for mediating nigrostriatal 
dopamine activity. + indicates excitatory effects upon receptor activation, and – indicates 
inhibitory effects upon receptor activation.  Note that the GABAergic projection from the 
globus pallidus externus to the STN has been omitted for clarity; however, activation of 
mAchRs on these incoming terminals has been shown to excite STN neurons by 
inhibiting GABA release in the STN (Shen and Johnson, 2000).  Thus, mAchRs located 
presynaptically on GABA terminals in the STN are receptors that mediate increases in 
dopamine activity not listed in this figure.  References corresponding to citation numbers: 
1: Picciotto et al., 1999; 2: Meltzer et al., 1997; 3: Schilstrom et al., 2003; 4: Paladini et 
al., 1999; 5: Forster et al., 2001; 6: Grillner and Mercuri, 2002; 7: Chergui et al., 1994; 8: 
Kearney and Albin, 2000; 9: Steiniger and Kretschmer, 2003; 10: Yin and French, 2000; 
11: Bonci and Malenka, 1999; 12: Manzoni and Williams, 1999; 13: Prior and Singh, 
2000; 14: Charara et al., 2000; 15: Miller and Blaha, 2004. 
 
 
Subcortical Involvement in PPT HFS-Evoked Nigrostriatal Dopamine Transmission 
The present results show that PPT HFS-evoked striatal dopamine release is significantly 
dependent on activities of the SNc and STN, as inactivation of the SNc or the STN both 
led to significant decreases in PPT-evoked striatal dopamine efflux compared to pre-drug 
infusion baseline responses.  Thus, these findings suggest that clinical DBS of the PPT 
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may involve activation of the SNc directly via excitatory PPT-SNc projections and 
indirectly via excitatory PPT-STN projections that, in turn, provide excitatory inputs to 
SNc dopamine cells.  The relative contributions of the direct and indirect projections to 
the SNc that are involved in mediating STN HFS-evoked dopamine release are 
summarized in Fig. 1B.  As expected PPT HFS-evoked dopamine release in the striatum 
is almost fully dependent upon activation of dopamine cells in the SNc, either directly or 
indirectly.  The present data again highlight the significance of the PPT-STN reciprocal 
connectivity, as neuronal projections through the STN mediate 50.0% of the PPT HFS-
evoked dopamine release in the striatum.  Thus, the present results suggest that the 
connectivity of the PPT and STN may be equally as important as the connectivity 
between the PPT and SNc; however, the neurochemical nature of this pathway has 
received historically less attention compared to the PPT-SNc projections.  For this reason, 
the present studies included experiments designed to distinguish the neurotransmitters 
involved in activating the STN following PPT HFS. 
 
STN receptor mechanisms mediating PPT HFS-evoked nigrostriatal dopamine 
transmission 
In further examining the excitatory glutamatergic and cholinergic pathway from the PPT 
to the STN, the present findings suggest that PPT HFS-evoked striatal dopamine release 
is dependent upon both glutamate receptors (GluRs) and acetylcholine receptors (AchRs) 
in the STN, as intra-STN GluR antagonists or AchR antagonists both significantly 
decreased PPT-evoked striatal dopamine release by 22.5% or 25.8%, respectively.  Thus, 
it seems that combined glutamatergic and cholinergic projections from the PPT to the 
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STN mediate approximately half of PPT-evoked dopamine release in the striatum.  
Although the use of broad-spectrum receptor antagonists in these studies precludes 
identification of specific receptor subtypes, both ionotropic and metabotropic GluRs 
(i/mGluRs) have been found in the STN (Gotz et al., 1997; Testa et al., 1994).  All iGluR 
subtypes, which are N-methyl-D-aspartic acid (NMDA), -amino-3-hydroxyl-5-methyl-
4-isoxazole-propionate (AMPA), and kainate (with the latter 2 sometimes collectively 
referred to as non-NMDA receptors), have been localized postsynaptically within the 
STN (Albin et al., 1989; Clarke and Bolam, 1998).  Activation of either NMDA and non-
NMDA receptors is thought to excite STN neurons, as studies utilizing in vitro slice 
preparations show that the application of both NMDA and non-NMDA glutamatergic 
antagonists reduce excitatory firing of STN neurons (Chergui et al., 1994; Shen and 
Johnson, 2000).  Future studies recording PPT HFS-evoked striatal dopamine release 
before and after intra-STN infusion of specific NMDA or AMPA/kainate receptor 
antagonists would help to determine the relative extent to which these iGluRs within the 
STN mediate pathways important to modulating striatal dopamine activity from PPT 
glutamatergic afferents.   
 The mGluRs are subdivided into 3 groups, I, II, and III, all of which are expressed 
to some degree in the STN (Testa et al., 1994).  The mGluRI and mGluRIII receptors are 
thought to be located postsynaptically and presynpatically, respectively, while the 
mGluRII are thought to be located both presynaptically and postsynaptically (Cartmell 
and Schoepp, 2000; Wang et al., 2000).  Activation of mGluRs in the STN has been 
shown to both increase and inhibit excitation of STN glutamate neurons (Abbott et al., 
1997; Awad et al., 2000; Awad-Granko and Conn, 2001).  Although the localization of 
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STN mGluRs and their role in mediating nigrostriatal dopamine release is unclear, it has 
been suggested that activation of presynaptic mGluRIII subtypes on glutamate terminals 
reduces STN activity while activation of postsynaptic mGluRII subtypes increases STN 
activity (Kearney and Albin, 2000).  The effects of STN mGluR activation on STN 
activity and dopamine-related behaviors appears to be occurring through several 
mechanisms that are still unclear (Kearney and Albin, 2000); therefore, future studies 
recording PPT HFS-evoked striatal dopamine release before and after infusion of 
selective mGluR antagonists would be useful in elucidating their role in mediating 
nigrostriatal dopamine transmission. 
The use of a combination of broad-spectrum AchR antagonists in the present 
studies also prevented identification of the specific STN muscarinic and nicotinic AchRs 
(m/nAchRs) utilized by PPT afferents to the STN.  Cholinergic agonists such as 
carbachol have been shown to excite STN neurons (Flores et al., 1996); however, nAchR 
agonists alone had no apparent effect on neuronal cell activity in the STN (Feger et al., 
1979).  Furthermore, the mAchR antagonist scopolamine, but not the nAchR antagonist 
mecamylamine, have been shown to block acetylcholine-evoked STN cell excitations 
(Feger et al., 1979); thus, it may be postulated that STN AchRs are primarily muscarinic 
(see Fig. 2). The M3 mAchR subtype, in particular, is prominently expressed in the STN 
(Levey et al., 1994), and Shen and Johnson (2000) found that the mAchR agonist 
muscarine reduced the amplitude of GABA inhibitory postsynaptic currents, while the 
effect was blocked by the non-subtype specific mAchR antagonist scopolamine as well as 
an M3 specific mAchR antagonist.  These investigators concluded that muscarinic 
agonists in the STN act at presynaptic M3 mAchRs on GABA afferents, causing 
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disinhibition (excitation) of STN neurons, thereby permitting afferents from the PPT to 
have a greater excitatory influence on STN output.  Thus, STN mAchRs, particularly of 
the M3 subtype, may be involved in the indirect activation of SNc dopaminergic cells via 
PPT-STN-SNc pathways (Shen and Johnson, 2000). 
 
SNc Receptor Mechanisms Mediating STN and PPT HFS-Evoked Nigrostriatal 
Dopamine Transmission 
Intra-SNc infusions of specific GluR and AchR antagonists helped to uncover the SNc 
receptor mechanisms that mediate STN and PPT HFS-evoked striatal dopamine release.  
The present findings suggest that activation of both GluRs and AchRs in the SNc is 
involved nigrostriatal dopamine transmission elicited by STN or PPT stimulation.  In 
regards to GluRs, the present results suggest that iGluRs in the SNc, compared to 
mGluRs, play a more critical role in mediating relatively brief excitatory glutamatergic 
activation of SNc dopamine neurons.  Fig. 2 illustrates i/mGluRs, m/nAchRs, and GABA 
receptors within the SNc and SNr responsible for mediating nigrostriatal dopamine 
activity.  Both NMDA and non-NMDA receptors were shown to be involved in STN 
HFS-evoked dopamine in the striatum, as evidenced by significantly attenuated responses 
following intra-SNc NMDA or AMPA/kainate receptor antagonists.  These findings were 
not surprising given that widespread distribution of both types of these subtype iGluRs on 
dopaminergic neurons in the SNc has been well established (Chatha et al., 2000).   
However, the present finding that infusion of an mGluR antagonist into the SNc 
had no effect on STN HFS-evoked dopamine release in the striatum warrants 
consideration.  Previous studies on the role of SNc mGluR receptors in nigrostriatal 
84 
 
dopamine activity are somewhat conflicting, as activation of mGluRs in the SNc has 
elicited both excitation and inhibition of nigrostriatal dopamine activity (Bonci et al, 
1997; Fiorillo and Williams, 1998; Guatteo et al, 1999; Meltzer et al., 1997; Wang et al., 
2005).  The mGluRI subtype is the predominant mGluR subtype localized to SNc 
dopamine cells (Kosinski et al., 1998; Testa et al., 1994); however, group II and III 
mGluRs are thought to be located presynaptically within the SNc (Mercuri et al., 1993).  
Activation of group II and III mGluRs on glutamate-containing terminals may attenuate 
dopamine cell activity by reducing excessive glutamate release onto dopamine cells in the 
SNc, despite a continuous level of firing activity (Grillner and Mercuri, 2002; Mercuri et 
al., 1993).  Indeed, continuous HFS of the STN has been shown to elicit a rapid increase 
in striatal dopamine release that quickly abates within two seconds of stimulation to 
approximately one-third the peak height of the initial increase (Lee et al., 2006), possibly 
reflecting a delayed inhibitory presynaptic regulation of glutamate release.  Thus, it is 
possible that the the relatively rapid (~1 sec duration) responses seen in the present 
studies utilizing in vivo fixed potential amperometry with STN-stimulation are not 
affected by the complex, relatively slower, actions of mGluRs.  Further studies utilizing 
longer term stimulation and selective mGluR antagonist infusions into the SNc are 
needed to clarify the role of these receptors mediating STN and/or PPT activation of SNc 
dopamine neurons, particularly in consideration that conventional DBS involves 
continuous stimulation of target structures. 
The use of broad-spectrum mAchR and nAchR antagonists in the present studies 
also did not permit identification of the specific receptor subtypes utilized by PPT 
afferents to the SNc.  However, excitation of midbrain dopaminergic neurons by 
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muscarine has been shown to be mediated by M1-like receptors (Lacey et al., 1990), and 
given that relatively high expression levels of mRNA for the M5 mAchR subtype in the 
SNc and the finding that the M5 subtype is the only mAchR to be definitively localized 
on SNc dopaminergic cells (Reever et al., 1997; Vilaro et al., 1990), SNc mAchRs of the 
M5 subtype are thought to be involved in the release of striatal dopamine following PPT 
stimulation (Forster et al., 2001; Forster and Blaha, 2003).  Nicotine administered locally 
into the SNc increases the firing of SNc dopaminergic neurons and enhances 
concentrations of dopamine metabolites in the striatum (Lichtensteiger et al., 1976, 
1982).  Several nAchR subunits, such as α3 to α7 and β2 to β3, have been shown to be 
present in the SNc (Champtiaux et al., 2002; Charpantier et al., 1998; Goldner et al., 
1997; Klink et al., 2001; Wonnacott et al., 2006).  In particular, cholinergic inputs from 
the PPT may enhance nigrostriatal dopaminergic transmission via activation of α4β2 and 
α7 nAchRs localized on dopaminergic cells in the SNc (Livingstone and Wonnacott, 
2009). 
 
Implications of the Current Findings to Parkinson’s Disease and DBS 
Furthering the current state of knowledge on the interconnectivity between important 
neural structures which can functionally influence nigrostriatal dopamine transmission 
allows for insight into potential pharmacological and surgical treatment of basal ganglia-
related disorders, such as Parkinson’s disease.  Results from the series of experiments in 
Chapters 5 and 6 add to the growing body of evidence supporting an important role of the 
STN and PPT in modulating striatal dopamine release and subsequent output from the 
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basal ganglia to the thalamus and motor areas of the cortex, thus influencing motor 
functioning. 
 
Glutamatergic and cholinergic receptor subtypes as targets for the treatment of 
Parkinson’s disease 
As the present results suggest that NMDA and AMPA/kainate receptors both play a 
significant role in modulating striatal dopamine release evoked by HFS of the STN, 
pharmacological manipulation of these receptors may be able to alter dysfunctional 
neurotransmission and thus provide a promising therapeutic target for treating 
Parkinson’s disease.  For example, antagonists of NMDA and AMPA receptors have 
been shown to reverse motor symptoms and levodopa-induced dyskinesias in 
parkinsonian animal models (Gossel et al., 1995; Klockgether and Turski, 1990; Schwarz 
et al., 1996).  Animal model studies also suggest that altering the activity of these 
receptors pharmaceutically may even serve to slow disease progression by delaying 
dopamine neuron degeneration, thought to be associated with excitotoxicity caused by 
relatively high extracellular levels of glutamate.  Specifically, NMDA receptors are 
known to mediate excitotoxicity caused by high levels of glutamate.  Therefore, 
activation of these receptors in the SNc may contribute to the degeneration of dopamine 
neurons in this region (Waxman and Lynch, 2005).  In support of this argument, NMDA 
antagonists have been noted to reduce or delay SNc degeneration and motor deficits 
caused by MPTP administration or 6-OHDA lesioning (Johnson et al., 2009).  Thus, 
blockade of NMDA receptors have been suggested to be a potentially useful strategy for 
slowing disease progression.  However, the widespread expression and diverse functional 
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roles of NMDA receptors raise concern that targeting these receptors would lead to 
serious unwanted side effects.  Clinical studies have therefore used weak NMDA receptor 
antagonists and have generally failed to find any therapeutic benefit when administered 
alone (without levodopa) (Johnson et al., 2009).  More promising studies suggest that 
selectively targeting NMDA receptor subtypes specific to regions relevant to Parkinson’s 
disease pathophysiology may represent safer neuroprotective options (Jin et al., 1997).  
As such, further clinical studies using more selective drugs targeting NMDA receptors 
are warranted.  Although blocking SNc mGluRs had no effect on relatively brief STN 
HFS-evoked striatal dopamine release in the present study, pharmaceutical modulation of 
mGluRs have shown promise in providing neuroprotection of SNc dopamine neurons in 
animal models of Parkinson’s disease (Johnson et al., 2009), further suggesting a role for 
mGluRs, located presynaptically on glutamate terminals in the STN, in maintaining 
functional non-toxic basal glutamate levels in the SNc (Grillner and Mercuri, 2002; 
Mercuri et al., 1993).  Therefore, GluRs represent promising targets for the development 
of nondopaminergic pharmaceutical therapies for the treatment of Parkinson’s disease, 
and more studies are necessary to determine the relative contributions of each receptor 
subtype in mediating afferent activation of the nigrostriatal dopamine system. 
Given the well known functional interactions of the cholinergic systems with the 
nigrostriatal dopaminergic system (for review see Lester et al., 2010), selective 
pharmaceutical agents acting on the various AchR subtypes existing heterogeneously at 
key anatomical sites in the brain also represent promising pharmaceutical targets in the 
treatment of Parkinson’s disease.  Historically, anticholinergics were the first available 
drugs for the alleviation of Parkinson’s symptoms, and are still used as secondary 
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treatments for Parkinson’s disease in conjunction with other antiparkinsonian drugs 
(Katzenschlager et al., 2003).  Centrally-acting anticholinergics, all specific for mAchRs, 
include benztropine (Cogentin), which is widely prescribed, and biperiden (Akineton), 
orphenadrine (Norflex), and procyclidine (no longer prescribed in the U.S.) (Deleu et al., 
2002).  Anticholinergic drugs have been used mainly in tremor-predominant cases of 
Parkinson’s disease and are thought to act by counterbalancing the reduced dopaminergic 
influence on the medium spiny GABAergic output neurons to the globus pallidus 
(Clarke, 2002; Lees, 2005).  Parkinsonian symptoms in mice induced by mAchR agonists 
can be reduced by systemic administration of a broad-spectrum mAchR antagonist, as 
well as a mAchR antagonist with moderate selectivity for the M4 mAchR (Betz et al., 
2007). 
Furthermore, findings that parkinsonian-like symptoms in mice can be reduced by 
systemic administration a broad-spectrum mAchR antagonist, as well as a mAchR 
antagonist with moderate selectivity for the M4 mAchR suggests that blockade of M4 
mAchR may be beneficial in reducing parkinsonian symptoms (Betz et al., 2007).  
However, systemic administration prevents the identification of the neural location at 
which the receptors are being blocked.  Intra-PPT infusions of the non-selective mAchR 
antagonist scopolamine enhances striatal dopamine release and dopamine-dependent 
behaviors such as locomotion and stereotypy; both of which can be blocked by the 
cholinergic agonist carbachol infused into the PPT (Chapman et al., 1997; Mathur et al., 
1997).  These mAchRs are most likely autoreceptors of the M2 family (M2 and M4) as 
M2 receptors have been localized presynaptically on PPT cholinergic neurons (Vilaro et 
al., 1992, 1994), and intra-PPT infusion of the M2/4 selective mAchR antagonist 
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methoctramine has been shown to enhance striatal dopamine release (Miller and Blaha, 
2004).  Therefore, M2/4 mAchRs are thought to function as cholinergic autoreceptors 
involved in feedback inhibition at the level of PPT cholinergic cells, regulating 
information received by the PPT.  Blocking these mAchR within the PPT and 
subsequently increasing PPT activation of SNc dopamine neurons may be therapeutically 
beneficial for treating the motor symptoms of Parkinson’s disease as reduced excitatory 
cholinergic output from the PPT has been found to result in parkinsonian-like postural 
deficits, hypokinesia, and locomotor deficits in primates (see Pahapill and Lozano, 2000).  
Furthermore, cholinergic neurons in the PPT are reduced by nearly 40% in Parkinson’s 
patients, and a significant loss of PPT neurons has been found to correlate with the extent 
of neuronal loss of dopaminergic cells in the SNc and the severity of Parkinson’s disease 
symptoms (Rinne et al., 2008; Zweig et al., 1989).  In sum, increasing activation of PPT 
neurons via blockade of mAchRs may relieve the motor symptoms of Parkinson’s disease 
by increasing activity of the remaining PPT projection neurons to SNc dopamine 
neurons. 
Findings from animal studies also suggest that nicotine or nAchR agonists may be 
an effective treatment for the motor symptoms of Parkinson’s disease.  Stimulation of 
nAchRs has been shown to modulate locomotor activity in intact nonlesioned animals as 
well as ameliorate motor dysfunctions in animals with nigrostriatal damage (Meshul et 
al., 2002; Schneider et al., 1998).  Additionally, studies have shown that people who 
smoke, or have smoked regularly, are 50% less likely to develop Parkinson’s disease than 
those who have never smoked, and nicotine has been found to alleviate parkinsonian 
cognitive and motor symptoms once Parkinson’s disease has developed (see Janhunen 
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and Ahtee, 2007).  The mechanisms underlying these therapeutically beneficial qualities 
of nicotine are not known.  Smoking and nicotine treatment have been shown to protect 
the nigrostriatal dopaminergic neurons from degeneration following MPTP or 6-OHDA 
treatment (Costa et al., 2001; Parain et al., 2003).  However, acute or short-term treatment 
with nicotine has shown little to no effects on motor activity in Parkinson’s patients or 
parkinsonian animal models, suggesting that nicotine treatment may only provide a 
neuroprotective and/or restorative effect with chronic use (see Quik et al., 2007).    
 
Mechanism of action of deep brain stimulation as a treatment for Parkinson’s disease 
The present studies show that HFS of the MFB, STN, or PPT elicits dopamine release in 
the dorsal striatum.  In relation to DBS as a treatment for Parkinson’s disease, the present 
findings add support for the “dopamine release” hypothesis which proposes that DBS 
improves motor symptoms related to Parkinson’s disease, in part, by activating surviving 
nigrostriatal dopamine neurons and subsequently increasing striatal dopamine release 
(Lee et al., 2009; Shah et al., 2010).  The present results indicate that MFB stimulation is 
mediated predominantly by activating ascending SNc dopamine axons, while STN 
stimulation evokes striatal dopamine release directly via excitatory glutamatergic inputs 
to SNc dopamine cells as well as, to a lesser degree, indirectly by activating excitatory 
glutamatergic and cholinergic STN-PPT-SNc pathways.  PPT stimulation evokes striatal 
dopamine release directly by activating glutamatergic and cholinergic pathways to SNc 
dopamine cells as well as indirectly via activation of glutamatergic and cholinergic PPT-
STN-SNc projections.  These data may help to explain the clinical improvements in 
motor symptoms of Parkinson’s patients following stimulation of the border and white 
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matter dorsal to the STN (notably the zona incerta) (Herzog et al., 2004; Saint-Cyr et al., 
2002; Voges et al., 2002) and may further suggest that DBS dorsal to the STN (within the 
MFB), rather than within the STN proper, may be optimal in increasing striatal dopamine 
levels for therapeutic benefits of Parkinson’s disease (Lee et al., 2006).   
The present findings also add further support for the PPT as a potential target for 
DBS as a treatment for certain motor symptoms of Parkinson’s disease, as PPT 
stimulation elicited dopamine release in the striatum similar in magnitude to that of STN 
stimulation.  The dual stimulation of the STN and PPT in clinical DBS procedures is an 
interesting and promising approach given the connectivity between the two nuclei 
highlighted in these studies (Stefani et al., 2007).  A better understanding of the neural 
connectivity and mechanisms involved in DBS could potentially revolutionize the 
procedure and lead to much greater clinical efficacy.  For example, expanding on the 
implications of the dopamine release hypothesis could lead to the next generation of DBS 
devices in which the system can monitor dopamine neurotransmission during stimulation, 
thus providing a neurochemical sensing feedback mechanism to maintain dopamine 
concentrations in the striatum at optimal levels for therapeutic efficacy (Lee et al., 2009). 
 
Future Directions and General Conclusions 
 Integrity of the nigrostriatal dopamine pathway is critical for the normal 
processing of sensory-motor information, with disruptions leading to neurological motor 
disorders, such as Parkinson’s disease.  The nigrostriatal dopamine pathway and other 
nuclei within the basal ganglia have many functionally critical interconnections as well as 
extensive connections with mesopontine glutamatergic and cholinergic pathways, to the 
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extent that pathology of the PPT is correlated with the motor symptoms of Parkinson’s 
disease (Rinne et al., 2008; Zweig et al., 1989).  The electrochemical technique applied in 
the experiments in Chapters 5 and 6 has provided a method with which to confirm and 
extend research investigating the neuronal pathways and receptor mechanisms involved 
in HFS-evoked nigrostriatal dopamine transmission.  Findings have thus indicated a 
complex role of glutamatergic and cholinergic afferents from the STN and PPT in 
modulating dopamine release in the striatum via direct and indirect routes to the SNc.  
Together with what is known of the physiological role of i/mGluRs and m/nAchRs in the 
STN, PPT, and SNc, results highlight the need for further development and application of 
selective ligands.   
The purpose of these studies was to explore the functional interconnectivity 
between nuclei involved in afferent regulation of nigrostriatal transmission. Therefore, it 
was necessary to use an intact brain, rather than in vitro slice preparations, so that normal 
neuronal influences on nigrostriatal dopamine release were maintained giving more 
ecological validity to the measures (Beurrier et al., 2006).  However, it has been noted 
that a possible limitation of in vivo monitoring is that it requires deep anaesthesia of 
animals which may increase the inhibitory responses of the central nervous system (West, 
1998).  However, this limitation has been minimized by the use of the anaesthetic 
urethane which has been shown to not interfere with dopamine functioning (Sabeti et al., 
2003).  Still, the evaluation of STN or PPT HFS-evoked striatal dopamine release, 
perhaps coupled with behavioral studies, in freely-moving animals would completely 
eliminate the issue of anaesthetic interference while further elucidating the behaviorally 
functional roles of the GluRs and AchRs identified in the present studies.  Furthermore, 
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as the present studies were conducted in intact animals, the applicability of the 
conclusions is limited.  Importantly, we have shown that HFS of the STN can elicit 
measurable dopamine release in the striatum of 6-OHDA lesioned animals, and the 
amount of HFS-evoked dopamine release correlated with the extent of 6-OHDA-induced 
denervation (Blaha et al., 2008).  Therefore, future experiments using the present 
neurochemical recording procedures in 6-OHDA lesioned mice are feasible and would 
provide knowledge of the involvement of these pathways in an animal model of 
Parkinson’s disease.   
Nonetheless, the findings of the present studies shed considerable light on the 
neural connectivity as well the receptor mechanisms involved in mediating HFS-evoked 
nigrostriatal dopamine transmission.  Understanding the influence of the STN and PPT 
on SNc dopamine cell activity and output of the basal ganglia-thalamocortical motor 
circuit may lead to novel pharmaceutical therapies as well as a better understanding of the 
underlying mechanisms of clinical DBS of the MFB, STN, and the interconnected PPT; 
both of which could lead to improvements the therapeutic efficacy of neuroprotective and 
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